- 68 Lozano R, Lopez AD, Atkinson C, Naghavi M, Flaxman AD, Murray CJ, and the Population Health Metrics Research Consortium (PHMRC). Performance of physician-certified verbal autopsies: multisite validation study using clinical diagnostic gold standards. Popul Health Metr 2011; 9: 32.
- 69 Bates M, O'Grady J, Mudenda V, Shibemba A, Zumla A. New global estimates of malaria deaths. *Lancet* 2012; 380: 560–61.
- 70 Lynch M, Korenromp E, Eisele T, et al. New global estimates of malaria deaths. *Lancet* 2012; 380: 559.
- 71 Shah NK, Kumar A, Valecha N. New global estimates of malaria deaths. *Lancet* 2012; 380: 560.
- 72 White NJ, Dondorp AM, Faiz A, Mishra S, Hien TT. New global estimates of malaria deaths. *Lancet* 2012; 380: 559–60.
- 73 Project Description. Global Enterics Mutli-Center Study (GEMS): University of Maryland School of Medicine. http://medschool. umaryland.edu/GEMS/ (accessed June 7, 2012).
- 74 WHO. Estimated rotavirus deaths for children under 5 years of age: 2008, 453 000. Geneva: World Health Organization, 2012. http://www.who.int/immunization_monitoring/burden/rotavirus_estimates/en/index.html (accessed July 6, 2012).
- 75 Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. *Lancet* 2010; 375: 1545–55.
- 76 Watt JP, Wolfson LJ, O'Brien KL, et al. Burden of disease caused by Haemophilus influenza type b in children younger than 5 years: global estimates. Lancet 2009; 374: 903–11.
- 77 Almirall J, Boixeda R, Bolíbar I, et al, and the GEMPAC Study Group. Differences in the etiology of community-acquired pneumonia according to site of care: a population-based study. Respir Med 2007; 101: 2168–75.
- 78 Díaz A, Barria P, Niederman M, et al. Etiology of community-acquired pneumonia in hospitalized patients in chile: the increasing prevalence of respiratory viruses among classic pathogens. Chest 2007; 131: 779–87.
- 79 Elliot AJ, Fleming DM. Influenza and respiratory syncytial virus in the elderly. Expert Rev Vaccines 2008; 7: 249–58.
- 80 Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005; 352: 1749–59.
- 81 Shibli F, Chazan B, Nitzan O, et al. Etiology of community-acquired pneumonia in hospitalized patients in northern Israel. Isr Med Assoc J 2010; 12: 477–82.
- 82 Köksal I, Ozlü T, Bayraktar O, et al, and the TUCAP Study Group. Etiological agents of community-acquired pneumonia in adult patients in Turkey; a multicentric, cross-sectional study. Tuberk Toraks 2010; 58: 119–27.
- 83 Maruyama T, Niederman MS, Kobayashi T, et al. A prospective comparison of nursing home-acquired pneumonia with hospital-acquired pneumonia in non-intubated elderly. *Respir Med* 2008; 102: 1287–95.
- 84 Maruyama T, Gabazza EC, Morser J, et al. Community-acquired pneumonia and nursing home-acquired pneumonia in the very elderly patients. *Respir Med* 2010; 104: 584–92.
- 85 Levine OS, O'Brien KL, Deloria-Knoll M, et al. The Pneumonia Etiology Research for Child Health Project: a 21st century childhood pneumonia etiology study. Clin Infect Dis 2012; 54 (suppl 2): S93–101.
- 86 Ganyaglo GYK, Hill WC. A 6-year (2004–2009) review of maternal mortality at the Eastern Regional Hospital, Koforidua, Ghana. Semin Perinatol 2012; 36: 79–83.
- 87 Almerie MQ, Matar HE, Almerie Y. A 20-year (1989–2008) audit of maternal mortality in Damascus, Syria. Int J Gynaecol Obstet 2011; 112: 70–71.
- 88 United Nations Millennium Development Goals. http://www. un.org/millenniumgoals/reports.shtml (accessed June 29, 2012).
- 89 Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. *Lancet* 2006; 367: 1066–74.
- 90 Waage J, Banerji R, Campbell O, et al. The Millennium Development Goals: a cross-sectoral analysis and principles for goal setting after 2015 Lancet and London International Development Centre Commission. *Lancet* 2010; 376: 991–1023.

- 91 Beaglehole R, Bonita R, Horton R, et al, and the Lancet NCD Action Group, and the NCD Alliance. Priority actions for the non-communicable disease crisis. *Lancet* 2011; 377: 1438–47.
- 92 Beaglehole R, Yach D. Globalisation and the prevention and control of non-communicable disease: the neglected chronic diseases of adults. *Lancet* 2003; 362: 903–08.
- 93 Daar AS, Singer PA, Persad DL, et al. Grand challenges in chronic non-communicable diseases. *Nature* 2007; 450: 494–96.
- 94 Nugent RA, Yach D, Feigl AB. Non-communicable diseases and the Paris Declaration. *Lancet* 2009; 374: 784–85.
- 95 Yach D. Nutritional change is not a simple answer to non-communicable diseases. BMJ 2011; 343: d5097.
- 96 Geneau R, Stuckler D, Stachenko S, et al. Raising the priority of preventing chronic diseases: a political process. *Lancet* 2010; 376: 1689–98.
- 97 Mock C, Joshipura M, Arreola-Risa C, Quansah R. An estimate of the number of lives that could be saved through improvements in trauma care globally. World J Surg 2012; 36: 959–63.
- 98 Go AS, Chertow GM, Fan D, McGulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296–305.
- 99 Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2224–60.
- 100 Murray CJL, King G, Lopez AD, Tomijima N, Krug EG. Armed conflict as a public health problem. BMJ 2002; 324: 346–49.
- 101 Frank C, Mohamed MK, Strickland GT, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000; 355: 887–91.
- 102 Zatoński WA, Sulkowska U, Mańczuk M, et al. Liver cirrhosis mortality in Europe, with special attention to Central and Eastern Europe. Eur Addict Res 2010; 16: 193–201.
- 103 WHO. Global health observatory data repository mortality, road traffic deaths. Geneva: World Health Organization, 2007. http://apps.who.int/ghodata/?vid=51210# (accessed July 5, 2012).
- 104 Roulson J, Benbow EW, Hasleton PS. Discrepancies between clinical and autopsy diagnosis and the value of post mortem histology; a meta-analysis and review. *Histopathology* 2005; 47: 551–59.
- 105 Sonderegger-Iseli K, Burger S, Muntwyler J. Diagnostic errors in three medical eras: a necropsy study. Lancet 2000; 355: 2027–31.
- 106 Autopsy as an outcome and performance measure: summary— AHRQ Evidence Report Summaries— NCBI Bookshelf. http:// www.ncbi.nlm.nih.gov/books/NBK11951/ (accessed June 29, 2012).
- 107 Verbal autopsy: innovations, applications, opportunities— Improving cause of death measurement. Popul Health Metr 2011; 9: 18-50
- 108 Flaxman AD, Vahdatpour A, Green S, James SL, Murray CJ, and the Population Health Metrics Research Consortium (PHMRC). Random forests for verbal autopsy analysis: multisite validation study using clinical diagnostic gold standards. Popul Health Metr 2011; 9: 29.
- 109 Murray CJ, James SL, Birnbaum JK, Freeman MK, Lozano R, Lopez AD, and the Population Health Metrics Research Consortium (PHMRC). Simplified symptom pattern method for verbal autopsy analysis: multisite validation study using clinical diagnostic gold standards. Popul Health Metr 2011; 9: 30.
- 110 James SL, Flaxman AD, Murray CJ, and the Population Health Metrics Research Consortium (PHMRC). Performance of the Tariff Method: validation of a simple additive algorithm for analysis of verbal autopsies. Popul Health Metr 2011; 9: 31.
- 111 Murray CJ, Lopez AD, Black R, et al. Population Health Metrics Research Consortium gold standard verbal autopsy validation study: design, implementation, and development of analysis datasets. Popul Health Metr 2011; 9: 27.
- 112 WHO. Health Metrics Network (HMN). Geneva: World Health Organization. http://www.who.int/healthmetrics/en/ (accessed July 10, 2012).

Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010



Theo Vos, Abraham D Flaxman, Mohsen Naghavi, Rafael Lozano, Catherine Michaud, Majid Ezzati, Kenji Shibuya, Joshua A Salomon, Safa Abdalla*, Victor Aboyans*, Jerry Abraham*, Ilana Ackerman*, Rakesh Aggarwal*, Stephanie Y Ahn*, Mohammed K Ali*, Mohammad A AlMazroa*, Miriam Alvarado*, H Ross Anderson*, Laurie M Anderson*, Kathryn G Andrews*, Charles Atkinson*, Larry M Baddour*, Adil N Bahalim*, Suzanne Barker-Collo*, Lope H Barrero*, David H Bartels*, Maria-Gloria Basáñez*, Amanda Baxter*, Michelle L Bell*, Emelia | Benjamin*, Derrick Bennett*, Eduardo Bernabé*, Kavi Bhalla*, Bishal Bhandari*, Boris Bikbov*, Aref Bin Abdulhak*, Gretchen Birbeck*, James A Black*, Hannah Blencowe*, Jed D Blore*, Fiona Blyth*, Ian Bolliger*, Audrey Bonaventure*, Soufiane Boufous*, Rupert Bourne*, Michel Boussinesg*, Tasanee Braithwaite*, Carol Brayne*, Lisa Bridgett*, Simon Brooker*, Peter Brooks*, Traolach S Brugha*, Claire Bryan-Hancock*, Chiara Bucello*, Rachelle Buchbinder*, Geoffrey Buckle*, Christine M Budke*, Michael Burch*, Peter Burney*, Roy Burstein*, Bianca Calabria*, Benjamin Campbell*, Charles E Canter*, Hélène Carabin*, Jonathan Carapetis*, Loreto Carmona*, Claudia Cella*, Fiona Charlson*, Honglei Chen*, Andrew Tai-Ann Cheng*, David Chou*, Sumeet S Chugh*, Luc E Coffeng*, Steven D Colan*, Samantha Colguhoun*, K Ellicott Colson*, John Condon*, Myles D Connor*, Leslie T Cooper*, Matthew Corriere*, Monica Cortinovis*, Karen Courville de Vaccaro*, William Couser*, Benjamin C Cowie*, Michael H Criqui*, Marita Cross*, Kaustubh C Dabhadkar*, Manu Dahiya*, Nabila Dahodwala*, James Damsere-Derry*, Goodarz Danaei*, Adrian Davis*, Diego De Leo*, Louisa Degenhardt*, Robert Dellavalle*, Allyne Delossantos*, Julie Denenbera*, Sarah Derrett*, Don C Des Jarlais*, Samath D Dharmaratne*, Mukesh Dherani*, Cesar Diaz-Torne*, Helen Dolk*, E Ray Dorsey*, Tim Driscoll*, Herbert Duber*, Beth Ebel*, Karen Edmond*, Alexis Elbaz*, Suad Eltahir Ali*, Holly Erskine*, Patricia J Erwin*, Patricia Espindola*, Stalin E Ewoigbokhan*, Farshad Farzadfar*, Valery Feigin*, David T Felson*, Alize Ferrari*, Cleusa P Ferri*, Eric M Fèvre*, Mariel M Finucane*, Seth Flaxman*, Louise Flood*, Kyle Foreman*, Mohammad H Forouzanfar*, Francis Gerry R Fowkes*, Richard Franklin*, Marlene Fransen*, Michael K Freeman*, Belinda J Gabbe*, Sherine E Gabriel*, Emmanuela Gakidou*, Hammad A Ganatra*, Bianca Garcia*, Flavio Gaspari*, Richard F Gillum*, Gerhard Gmel*, Richard Gosselin*, Rebecca Grainger*, Justina Groeger*, Francis Guillemin*, David Gunnell*, Ramyani Gupta*, Juanita Haaqsma*, Holly Haqan*, Yara A Halasa*, Wayne Hall*, Diana Harinq*, Josep Maria Haro*, James E Harrison*, Rasmus Havmoeller*, Roderick J Hay*, Hideki Higashi*, Catherine Hill*, Bruno Hoen*, Howard Hoffman*, Peter J Hotez*, Damian Hoy*, John J Huang*, Sydney E Ibeanusi*, "Kathryn H Jacobsen*, Spencer L James*, Deborah Jarvis*, Rashmi Jasrasaria*, Sudha Jayaraman*, Nicole Johns*, Jost B Jonas*, Ganesan Karthikeyan*, Nicholas Kassebaum*, Norito Kawakami*, Andre Keren*, Jon-Paul Khoo*, Charles H King*, Lisa Marie Knowlton*, Olive Kobusingye*, Adofo Koranteng*, Rita Krishnamurthi*, Ratilal Lalloo*, Laura L Laslett*, Tim Lathlean*, Janet L Leasher*, Yong Yi Lee*, James Leigh*, Stephen S Lim*, Elizabeth Limb*, John Kent Lin*, Michael Lipnick*, Steven E Lipshultz*, Wei Liu*, Maria Loane*, Summer Lockett Ohno*, Ronan Lyons*, Jixiang Ma*, Jacqueline Mabweijano*, Michael F MacIntyre*, Reza Malekzadeh*, Leslie Mallinger*, Sivabalan Manivannan*, Wagner Marcenes*, Lyn March*, David J Margolis*, Guy B Marks*, Robin Marks*, Akira Matsumori*, Richard Matsopoulos*, Bongani M Mayosi*, John H McAnulty*, Mary M McDermott*, Neil McGill*, John McGrath*, Maria Elena Medina-Mora*, Michele Meltzer*, Ziad A Memish*, George A Mensah*, Tony R Merriman*, Ana-Claire Meyer*, Valeria Miglioli*, Matthew Miller*, Ted R Miller*, Philip B Mitchell*, Ana Olga Mocumbi*, Terrie E Moffitt*, Ali A Mokdad*, Lorenzo Monasta*, Marcella Montico*, Maziar Moradi-Lakeh*, Andrew Moran*, Lidia Morawska*, Rintaro Mori*, Michele E Murdoch*, Michael K Mwaniki*, Kovin Naidoo*, M Nathan Nair*, Luigi Naldi*, K M Venkat Narayan*, Paul K Nelson*, Robert G Nelson*, Michael C Nevitt*, Charles R Newton*, Sandra Nolte*, Paul Norman*, Rosana Norman*, Martin O'Donnell*, Simon O'Hanlon*, Casey Olives*, Saad B Omer*, Katrina Ortblad*, Richard Osborne*, Doruk Ozgediz*, Andrew Page*, Bishnu Pahari*, Jeyaraj Duraj Pandian*, Andrea Panozo Rivero*, Scott B Patten*, Neil Pearce*, Rogelio Perez Padilla*, Fernando Perez-Ruiz*, Norberto Perico*, Konrad Pesudovs*, David Phillips*, Michael R Phillips*, Kelsey Pierce*, Sébastien Pion*, Guilherme V Polanczyk*, Suzanne Polinder*, C Arden Pope III*, Svetlana Popova*, Esteban Porrini*, Farshad Pourmalek*, Martin Prince*, Rachel L Pullan*, Kapa D Ramaiah*, Dharani Ranganathan*, Homie Razavi*, Mathilda Regan*, Jürgen T Rehm*, David B Rein*, Guiseppe Remuzzi*, Kathryn Richardson*, Frederick P Rivara*, Thomas Roberts*, Carolyn Robinson*, Felipe Rodriquez De Leòn*, Luca Ronfani*, Robin Room*, Lisa C Rosenfeld*, Lesley Rushton*, Ralph L Sacco*, Sukanta Saha*, Uchechukwu Sampson*, Lidia Sanchez-Riera*, Ella Sanman*, David C Schwebel*, James Graham Scott*, Maria Sequi-Gomez*, Saeid Shahraz*, Donald S Shepard*, Hwashin Shin*, Rupak Shivakoti*, David Singh*, Gitanjali M Singh*, Jasvinder A Singh*, Jessica Singleton*, David A Sleet*, Karen Sliwa*, Emma Smith*, Jennifer L Smith*, Nicolas J C Stapelberg*, Andrew Steer*, Timothy Steiner*, Wilma A Stolk*, Lars Jacob Stovner*, Christopher Sudfeld*, Sana Syed*, Giorgio Tamburlini*, Mohammad Tavakkoli*, Hugh R Taylor*, Jennifer A Taylor*, William J Taylor*, Bernadette Thomas*, W Murray Thomson*, George D Thurston*, Imad M Tleyjeh*, Marcello Tonelli*, Jeffrey A Towbin*, Thomas Truelsen*, Miltiadis K Tsilimbaris*, Clotilde Ubeda*, Eduardo A Undurraga*, Marieke J van der Werf*, Jim van Os*, Monica S Vavilala*, N Venketasubramanian*, Mengru Wang*, Wenzhi Wang*, Kerrianne Watt*, David J Weatherall*, Martin A Weinstock*, Robert Weintraub*, Marc G Weisskopf*, Myrna M Weissman*, Richard A White*, Harvey Whiteford*, Steven T Wiersma*, James D Wilkinson*, Hywel C Williams*, Sean R M Williams*, Emma Witt*, Frederick Wolfe*, Anthony D Woolf*, Sarah Wulf*, Pon-Hsiu Yeh*, Anita K M Zaidi*, Zhi-Jie Zheng*, David Zonies*, Alan D Lopez†, Christopher J L Murray†‡

Summary

Background Non-fatal health outcomes from diseases and injuries are a crucial consideration in the promotion and Lancet 2012; 380: 2163-96 monitoring of individual and population health. The Global Burden of Disease (GBD) studies done in 1990 and 2000 have been the only studies to quantify non-fatal health outcomes across an exhaustive set of disorders at the global and regional level. Neither effort quantified uncertainty in prevalence or years lived with disability (YLDs).

Methods Of the 291 diseases and injuries in the GBD cause list, 289 cause disability. For 1160 sequelae of the 289 diseases and injuries, we undertook a systematic analysis of prevalence, incidence, remission, duration, and excess mortality. Sources included published studies, case notification, population-based cancer registries, other disease registries, antenatal clinic serosurveillance, hospital discharge data, ambulatory care data, household surveys, other surveys, and cohort studies. For most sequelae, we used a Bayesian meta-regression method, DisMod-MR,

This online publication has been corrected. The corrected version first appeared at thelancet.com on February 22, 2012

See Comment pages 2053, 2054, 2055, 2058, 2060, 2062,

See Special Report page 2067

See Articles pages 2071, 2095, 2129, 2144, 2197, and 2224

*Authors listed alphabetically

†Joint senior authors

‡Corresponding author

See Online for appendix

For interactive versions of figures 2, 4, 5, and 6 see http:// healthmetricsandevaluation.org/qbd/visualizations/regional

Queensland Centre for Mental Health Research (A Baxter MPH, H Erskine BPsvSc. A Ferrari BPsySc, J-P Khoo MBBS, S Saha PhD. Prof H Whiteford MBBS), School of Population Health (Prof T Vos PhD. I D Blore PhD. F Charlson MPH, H Higashi PhD. YY Lee MHEcon, R Norman PhD. A Page PhD. Prof A D Lopez PhD). Centre for Clinical Research (LG Scott PhD), Queensland **Brain Institute** (Prof | McGrath MD), University of Oueensland, Brisbane, OLD. Australia (B Garcia MPH. Prof W Hall PhD): Institute for Health Metrics and Evaluation (A D Flaxman PhD. M Naghayi PhD. Prof R Lozano MD. SY Ahn MPH.

M Alvarado BA. K G Andrews MPH C Atkinson BS, I Bolliger AB. R Burstein BA, B Campbell BA, D Chou BA, K E Colson BA. Prof S D Dharmaratne MBBS, A Delossantos BS. M H Forouzanfar MD. M K Freeman BA, E Gakidou PhD. D Haring BS, S L James MPH, R Jasrasaria BA, N Johns BA. S Lim PhD, S Lockett Ohno BA. M F MacIntyre EdM, L Mallinger MPH, A A Mokdad MD, M N Nair MD. K Ortblad BA, D Phillips BS, K Pierce BA, D Ranganathan BS, T Roberts BA, L C Rosenfeld MPH. E Sanman BS, M Wang MPH, S Wulf MPH. Prof C J L Murray MD), Department of Epidemiology, School of Public Health (L M Anderson PhD). Department of Anesthesiology and Pain Medicine (N Kassebaum MD), University of Washington, Seattle, WA, USA (Prof W Couser MD. H Duber MD. B Ebel MD. C Olives PhD, Prof F P Rivara MD, B Thomas MD, Prof M S Vavilala MD); China Medical Board, Boston, MA, USA (C Michaud MD); MRC-HPA

Centre for Environment and Health, Department of

Biostatistics, School of Public

Epidemiology and

designed to address key limitations in descriptive epidemiological data, including missing data, inconsistency, and large methodological variation between data sources. For some disorders, we used natural history models, geospatial models, back-calculation models (models calculating incidence from population mortality rates and case fatality), or registration completeness models (models adjusting for incomplete registration with health-system access and other covariates). Disability weights for 220 unique health states were used to capture the severity of health loss. YLDs by cause at age, sex, country, and year levels were adjusted for comorbidity with simulation methods. We included uncertainty estimates at all stages of the analysis.

Findings Global prevalence for all ages combined in 2010 across the 1160 sequelae ranged from fewer than one case per 1 million people to 350 000 cases per 1 million people. Prevalence and severity of health loss were weakly correlated (correlation coefficient –0·37). In 2010, there were 777 million YLDs from all causes, up from 583 million in 1990. The main contributors to global YLDs were mental and behavioural disorders, musculoskeletal disorders, and diabetes or endocrine diseases. The leading specific causes of YLDs were much the same in 2010 as they were in 1990: low back pain, major depressive disorder, iron-deficiency anaemia, neck pain, chronic obstructive pulmonary disease, anxiety disorders, migraine, diabetes, and falls. Age-specific prevalence of YLDs increased with age in all regions and has decreased slightly from 1990 to 2010. Regional patterns of the leading causes of YLDs were more similar compared with years of life lost due to premature mortality. Neglected tropical diseases, HIV/AIDS, tuberculosis, malaria, and anaemia were important causes of YLDs in sub-Saharan Africa.

Interpretation Rates of YLDs per 100 000 people have remained largely constant over time but rise steadily with age. Population growth and ageing have increased YLD numbers and crude rates over the past two decades. Prevalences of the most common causes of YLDs, such as mental and behavioural disorders and musculoskeletal disorders, have not decreased. Health systems will need to address the needs of the rising numbers of individuals with a range of disorders that largely cause disability but not mortality. Quantification of the burden of non-fatal health outcomes will be crucial to understand how well health systems are responding to these challenges. Effective and affordable strategies to deal with this rising burden are an urgent priority for health systems in most parts of the world.

Funding Bill & Melinda Gates Foundation.

Introduction

Non-fatal health outcomes from diseases and injuries are a crucial consideration in the promotion and monitoring of individual and population health. In an era in which the Millennium Development Goals (MDGs) have refocused global health attention on prevention of mortality from selected disorders, it is important to emphasise that health is about more than avoiding death. Individuals, households, and health systems devote enormous resources to the cure, prevention, and amelioration of non-fatal sequelae of diseases and injuries. Some form of periodic accounting about the burden of non-fatal illness in populations, and how it is changing, should therefore be available for policy making and planning. Quantification of the burden of non-fatal health outcomes was one of the main goals in launching the Global Burden of Disease study (GBD) in the 1990s.1 The study introduced the disability-adjusted life-year (DALY) as a time-based measure of health that enables commensurable measurement of years of life lost due to premature mortality (YLLs) with years of life lived in less than ideal health (years lived with disability [YLDs]). The amalgamation of both components of individual and population health under a comprehensive framework for measuring population health can provide important insights into a broader set of causes of disease burden than can consideration of mortality alone.

To our knowledge, the various revisions of the GBD are the only effort to quantify non-fatal health outcomes across an exhaustive set of disorders at the global and regional level.²⁻⁸ Many national burden of disease studies and subnational studies have analysed local patterns of YLDs as well.⁹⁻¹⁶ Publication of the GBD 1990 results raised awareness about a range of disorders that primarily cause ill health and not death, such as unipolar major depression, bipolar disorder, asthma, and osteoarthritis.¹⁷⁻¹⁹ This attention has led to greater policy debate and action on mental health and other non-communicable diseases at WHO,^{4,20,21} in non-governmental organisations, and in many countries.²² The burden of non-fatal illness attributed to some parasitic diseases has also been an important issue highlighted by the GBD findings.²³⁻²⁶

Despite the unique role of the GBD in provision of comparative quantification of the burden of non-fatal health outcomes, there have been important limitations. The evidence on MDG-related diseases has been regularly revised and incorporated into updates of the GBD, but many disorders have not been systematically analysed since 1990. Global Health Statistics, a companion volume to the original Global Burden of Disease and Injuries book, provided estimates of incidence, prevalence, remission, and case fatality for 483 sequelae, by age and sex, for eight regions of the world.²⁷ The GBD 2000 revisions included 474 sequelae. A substantial number, but not all, of these sequelae were revised since GBD 1990. Those that were

not revised were approximated with constant relations between YLLs and YLDs or YLD rates estimated from the GBD 1990. Even when revisions were undertaken, however, many were not based on systematic analyses of published studies and unpublished sources. The epidemiological inputs to YLD estimates such as prevalence have been released for only 40 sequelae. The most important limitation of both the GBD 1990 and 2000 efforts is that YLDs have not been estimated with uncertainty. Uncertainty can come from many sources, including heterogeneity in the empirical data that are available and uncertainty in the indirect estimation models used to make predictions for populations with little or no data. Because the empirical basis for estimating prevalence or incidence is much weaker for some sequelae than it is for others, uncertainty is likely to vary substantially across sequelae and across countries and regions for the same sequelae.8,28

The Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) provided an important opportunity to address the key limitations of past burden of disease assessments, including a more standardised approach to evidence synthesis, epidemiological estimation with uncertainty, and assessment of comorbidity. In this Article, we describe the approach to undertaking these analyses with the available evidence, and discuss key comparative results. Subsequent disease-specific and injury-specific papers are planned that will provide much more detail on data, methods, and results for various disorders of interest.

Methods

Overview

Details of the GBD 2010 hierarchical cause list, the 21 epidemiological regions (and combinations of these into seven super-regions), the 20 age groups, and the relation between different components of GBD 2010 are published elsewhere.29 For the GBD 2010, YLDs are computed as the prevalence of a sequela multiplied by the disability weight for that sequela without age weighting or discounting. The YLDs arising from a disease or injury are the sum of the YLDs for each of the sequelae associated with that disease. Across the 291 diseases and injury causes in the study, 289 cause disability-for these causes there were 1160 sequelae that captured the major outcomes of these diseases and injuries.^{29,30} The key analytical task for the study was to estimate the prevalence with uncertainty of each of the 1160 sequelae for 20 age groups, both sexes, and 21 regions for 1990, 2005, and 2010. See panel for terminology used in GBD 2010.

For each disease or injury, we identified the key sequelae from that cause. Sequelae could include the disease itself, such as diabetes, or the outcomes associated with that disease such as diabetic foot, neuropathy, or retinopathy. Some clinical disorders were classified as a disease but also can be a consequence of another disease-eg, chronic kidney disease secondary to diabetes is a

Panel: Terminology used in the Global Burden of Disease study (GBD)

Disability

Disability refers to any short-term or long-term health loss. Many other definitions of disability are in use such as those in the WHO World Report on Disabilities.³¹ These definitions often stress moderate to severe health loss and the role of the environment in the loss of individuals' wellbeing.

In the GBD 2010 cause list there are 291 diseases and injuries, of which 289 cause disability. In total, we have identified 1160 sequelae of these diseases and injuries. For example, diabetic neuropathy is a sequela of diabetes mellitus. To avoid double counting, a sequela can only be counted in the cause list once even if the same outcome might be caused by more than one disease.

Health state

Across the 1160 sequelae, we identified 220 unique health states. For example, both malaria and hookworm have mild anaemia as a sequela. Mild anaemia is a unique health state. The list of unique health states serves two purposes: to allow assessment of the total burden of some health states such as anaemia across various causes, and to simplify the task of measuring disability weights for sequelae.

Disability weights

A quantification of the severity of health loss associated with the 220 unique health states on a scale from 0 to 1, when 0 is commensurate with perfect health and 1 is commensurate with death. In the GBD 2010, disability weights for health states are measured based on survey respondents representing the general public.

Years lived with disability (YLDs)

For the GBD 2010, YLDs per person from a sequela are equal to the prevalence of the sequela multiplied by the disability weight for the health state associated with that seguela. YLDs for a disease or injury are the sum of the YLDs for each sequela associated with the disease or injury.

In the GBD 2010 we estimated the prevalence and burden of several unique health states that are sequelae for multiple diseases including anaemia, heart failure, vision loss, seizures, hearing loss, infertility, and intellectual disability. These are referred to as impairments.

consequence of diabetes but was classified as a disease. Any given outcome appears in the GBD cause and sequela list only once to avoid double counting of the associated burden. Across the 1160 sequelae, we identified 220 unique health states, representing a parsimonious list providing enough detail to describe the large variations between health states while still a manageable number for which we were able to derive disability weights by survey. In principle, we estimated YLDs at the level of an individual and then assigned individual health loss to all the contributing sequelae present in an individual. The analysis can be divided into seven specific steps (figure 1) which are briefly described below.

Identification and documentation of data sources

The analysis for each sequela began with the identification and documentation of sources of data for incidence, prevalence, remission, duration, and excess mortality. We used nine types of data sources. First, contributors to the GBD have undertaken systematic reviews for disease sequelae. For example, for epilepsy we retrieved:

Health (Prof M Ezzati PhD), Imperial College London, London, UK (Prof M-G Basáñez PhD. Prof P Burney MD, K Foreman MPH, D Jarvis FFPH, S O'Hanlon MSc, L Rushton PhD); Department of Global Health Policy (Prof K Shibuya MD), University of Tokyo, Tokyo, Japan (Prof N Kawakami MD); Department of Biostatistics (M M Finucane PhD), School of Public Health (Prof J A Salomon PhD, G Danaei MD, J K Lin AB, M Miller MD, G M Singh PhD, C Sudfeld ScM, M Tavakkoli MD, M G Weisskopf PhD, R A White MA), Department of Epidemiology (W Liu MD), Harvard Humanitarian Initiative (L M Knowlton MD), Boston Children's Hospital (Prof S D Colan MD), Brigham and Women's Hospital




Figure 1: Overview of the seven steps in the estimation of prevalence and years lived with disability (YLDs) DW=disability weight.

(S Jayaraman MD), Harvard Medical School, Harvard University, Boston, MA, USA (D H Bartels BA, K Bhalla PhD); Sudanese Public Health Consultancy Group, Sudan (S Abdalla MBBS); Department of Cardiology, Dupuytren University Hospital, Limoges, France (Prof V Aboyans MD); University of Texas, San Antonio, TX, USA (J Abraham MPH); Centre for International Child Health (A Steer MBBS), Department of Paediatrics (R Weintraub MBBS),

230 prevalence studies from 83 countries in all 21 world regions, a further 97 studies of incidence, 25 studies of the mortality risk in people with epilepsy, and only one study on remission meeting inclusion criteria. For other disease sequelae, only a small fraction of the existing data appear in the published literature, and other sources predominate such as local surveys of schistosomiasis prevalence or antenatal clinic serosurveillance for HIV/AIDS. Second, reports to governments of cases have been used for African trypanosomiasis, measles, pertussis, tuberculosis, leprosy, dengue, cholera, and yellow fever. Use of these data for burden of disease assessment required explicit modelling of the case detection rate for every disease. Third, we used

population-based disease registry data for cancers,32-40 chronic kidney diseases, multiple sclerosis,41 Parkinson's disease, 42,43 and congenital anomalies.44 Cancer registries have been established in many developed countries and are being rapidly established in developing countries. For example, by the end of 2010, cancer registries had expanded in China to 149 registries covering 31 provinces:45 India now has 23 registries.46 Fourth, many countries, in collaboration with UNAIDS and WHO, have established networks of antenatal clinics that test women presenting for antenatal care for HIV, syphilis, and other disorders. Fifth, for 43 countries, we obtained hospital discharge data coded to ICD9 or ICD10. Use of these data required an explicit model of selection bias to take into account variations in access to care. Additionally, for chronic diseases, we had to estimate the average number of admissions to hospital per person per year with a disease to interpret the results. We analysed datasets with unique identifiers for every patient for seven US states from 2003 to 2007 for cirrhosis and pneumoconiosis. Hospital discharge data were an important source for acute disorders such as stroke, myocardial infarction, appendicitis, or pancreatitis, and for injuries. Sixth, for skin diseases and other mental and behavioural disorders, outpatient data collected in health systems with nearly complete or at least representative samples of ambulatory data⁴⁷⁻⁵⁵ have also been used after taking into account selection bias. Seventh, we used interview questions, direct measurements (eg, hearing, vision, and lung function testing), serological measurements, and anthropometry from the re-analysis of multiple household surveys. Surveys of selected populations such as school children for intellectual disability,56 nursing home residents for dementia,57 or mental health clinic attendees for schizophrenia58 have also been used after taking into consideration selection bias. Eighth, re-analysis of cohort or follow-up studies has been used for some causes such as impairment due to injury. We also used cohort studies to provide information about remission rates, duration, and mortality risks for many chronic disorders. Finally, we used indirect prevalence studies as an input to estimate the total number of drug users.⁵⁹ These estimates were produced from a combination of multiplier, capture-recapture, and backprojection methods combining data from treatment centres, police records, court records, and survey data.

Developing prevalence estimates for sequelae

Meta-analysis or meta-regression of descriptive epidemiological studies oposes many challenges. First, for many regions and for many sequelae data are scarce. Predictions of prevalence need to take advantage of relations with covariates in a meta-regression or default to the average of a region, super-region, or the world. Second, in settings with multiple measurements, study results can be highly heterogeneous because of much non-sampling error. Sources of non-sampling error include selection bias in the population studied, study design, implementation issues in data collection, widely varying case definitions

across studies, and the use of different diagnostic technologies or laboratory techniques. Third, available studies have often used diverse age groups like 17-38 years or 15 years and above. Fourth, data for various disorders were collected for many different outcomes such as incidence, prevalence, remission, excess mortality, or cause-specific mortality. The mix of data varies across diseases and across regions for a disease. All of these sources provide some relevant information for the estimation of prevalence. Fifth, within regions or countries, the true prevalence of a sequela can vary enormously. Sixth, on the basis of biology or clinical series, there might be strong prior views on the age pattern of incidence or prevalence for a disorder that should be reflected in the results. For instance, we would not expect prevalence of Alzheimer's disease before age 40 years and diagnostic rules stipulate that the onset of attention deficit and hyperactivity disorder cannot occur before age 4 years or after age 8 years.64

To address these challenges, we have developed a Bayesian meta-regression method, DisMod-MR, which estimates a generalised negative binomial model for all epidemiological data. The model includes the following: covariates that predict variation in true rates; covariates that predict variation across studies because of measurement bias; super-region, region, and country random intercepts; and age-specific fixed effects. When appropriate, the rates were assumed to have been constant over time, which allowed data for incidence, prevalence, excess mortality, and cause-specific mortality to inform prevalence estimates. The differential equations governing the relation between the parameters of incidence, remission, mortality, prevalence, and duration are well characterised. 65,66 DisMod-MR can use data reported for any age group to inform the maximum likelihood estimate. We used a large set of 179 covariates that have been appropriately imputed so that the data provide a complete time series for all 187 countries in the analysis (see the appendix for details of the estimation equations used for DisMod-MR and the approach to numerical solution, as well as an example of its application).29

For cancer incidence and prevalence, we used the approach applied by Forouzanfar and colleagues67 to breast and cervical cancers. We estimated the mortalityto-incidence ratio for each cancer for all country, age, and sex groups using data from all high-quality registries that reported on both incidence and mortality. We developed separate models for both sexes. Cause of death estimates for each cancer by country, year, age, and sex68 were divided by the predicted mortality-to-incidence ratio to generate incidence estimates. To estimate the prevalence of each of four sequelae of cancer including: diagnosis or treatment phase, remission, recurrence, and terminal phase, we estimated the natural history of incident cases using a calculated 5 year survival and relative duration of each cancer phase. We also used a variant of this approach to estimate incidence and prevalence for visceral leishmaniasis.

We used four sets of alternative methods for some disorders because of variation in the types of data available and the complexity of their spatial and temporal distributions (see appendix for further details). For HIV/ AIDS, we used the UNAIDS natural history model developed with the Spectrum platform. 69,70 Detailed estimates of prevalence and mortality with uncertainty by age and sex have been provided based on the 2012 revision of HIV/AIDS epidemiology. We developed natural history models for measles and pertussis. For ascariasis, trichuriasis, hookworm, and schistosomiasis, prevalence of the disease has been estimated with geospatial estimation methods.71-73 For diphtheria, tetanus, and rabies, we have used systematic reviews of data for case-fatality rates with estimates of mortality to estimate incidence—the mortality estimates for these diseases are described elsewhere.68 For these disorders, DisMod-MR was used as a meta-regression method to estimate the case-fatality rate by age, sex, and region. For tuberculosis and dengue, the key source of information was registered cases. We developed statistical models that simultaneously model the expected rates as a function of covariates and the undercount of cases as a function of health system access.

Severity distributions

For 41 diseases, the sequelae of the disease have been linked to more than one health state including stroke, anxiety, major depressive disorder, symptomatic heart failure, and chronic obstructive pulmonary disease (COPD). After analysing the prevalence of the overall disorder, we estimated the distribution of these prevalent cases across severity levels. Disability weights were measured in population surveys30 for individuals without comorbidity. Two estimates are needed to calculate YLDs: the disability weight for individuals with a single sequela and the disability weight for individuals with multiple sequelae, which is a common occurrence. The prevalence of comorbid disorders can be estimated with micro-simulation. However, we needed to estimate the distribution of severity controlling for comorbidity, otherwise the severity distribution would be systematically biased towards more severe symptoms caused by comorbidity. For example, if individuals with depression are also likely to have anxiety and substance-use disorders, the reported distribution of functional health status would be shifted towards the more severe end.

Data for severity distributions are often scarcer and of poorer quality than are data for prevalence of disorders, with some exceptions. Approaches to severity classification are inconsistent across disorders. Because of the heterogeneity of the available evidence for disease severity, we supplemented disease specific reviews with an analysis of three data sources: the US Medical Expenditure Panel Survey (MEPS) 2000–09, the US National Epidemiological Survey on Alcohol and Related Conditions (NESARC) 2000–01 and 2004–05, and the Australian National Survey of Mental Health and Wellbeing of Adults (AHS) 1997.

Centre for Health Policy. Programs and Economics (Prof L Degenhardt PhD), School of Population Health (Prof R Room PhD), University of Melbourne, Melbourne, VIC, Australia (I Ackerman PhD, Prof P Brooks MD. Prof R Marks MBBS Prof H R Taylor MD); Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India (Prof R Aggarwal MD); Schools of Public Health and Medicine (S B Omer MBBS). Emory University, Atlanta, GA, USA (M K Ali MBChB. K C Dabhadkar MBBS, K M V Narayan MD, H A Ganatra MBBS); Ministry of Health, Riyadh, Saudi Arabia (M A AlMazroa MD Prof Z A Memish MD): St George's University of London, London, UK (Prof H R Anderson MD. R Gupta MSc, E Limb MSc); Mayo Clinic, Rochester, MN, USA (Prof L M Baddour MD, P J Erwin MLS, Prof S E Gabriel MD); Independent Consultant, Geneva, Switzerland (A N Bahalim MEng); University of Auckland, Auckland, New Zealand (S Barker-Collo PhD); Department of Industrial Engineering, School of Engineering, Pontificia Universidad Javeriana, Bogota, Colombia (L H Barrero ScD); Global Partners in Anesthesia and Surgery (D Ozgediz MD), Yale University, New Haven, CT, USA (Prof M L Bell PhD, JJ Huang MD); School of Medicine (Prof DT Felson MD), Boston University, Boston, MA, USA (Prof E J Benjamin MD); Clinical Trial Service Unit and **Epidemiological Studies Unit** (D Bennett PhD), University of Oxford, Oxford, UK (Prof C R Newton MD D J Weatherall MD); Dental Institute (E Bernabé PhD), Hospital NHS Trust (Prof R J Hay DM), Institute of Psychiatry, King's College London, London, UK (Prof M Prince MD); Institute of Dentistry (M Dahiya BDS), Queen Mary University of London, London, UK (B Bhandari MSc. Prof W Marcenes PhD): Moscow State University of Medicine and Dentistry, Research Institute of Transplantology and Artificial Organs, Moscow, Russia (B Bikbov MD); King

Fahad Medical City, Riyadh, Saudi Arabia (A Bin Abdulhak MD, I M Tleyjeh MD); Michigan State University, East Lansing, MI, USA (Prof G Birbeck MD); MRC Epidemiology Unit, Cambridge,

UK (J A Black MPhil); London School of Hygiene and Tropical Medicine, London, UK (Prof S Brooker DPhil, H Blencowe MBChB, K Edmond PhD, Prof N Pearce PhD, R L Pullan PhD, J L Smith MSc); Department of Rheumatology, Northern Clinical School (E Smith PhD), Faculty of Health Sciences (M Fransen PhD), Institute of Bone and Joint Research (Prof L March MD. L Sanchez-Riera MD), Sydney School of Public Health (T Driscoll PhD, J Leigh MBBS), University of Sydney, Sydney, NSW, Australia (F Blyth PhD, L Bridgett PhD, M Cross PhD, Prof G B Marks PhD. N McGill FRACP); Inserm, Paris, France (A Bonaventure MD. A Elbaz MD): Transport and Road Safety Research (S Boufous PhD), National Drug and Alcohol Research Centre (B Calabria BPsych, Prof L Degenhardt, P.K. Nelson MHSc. | Singleton MIPH), University of New South Wales, Sydney, NSW. Australia (C Bucello BPsvc. Prof P B Mitchell MD): Vision and Eye Research Unit, Anglia Ruskin University, Cambridge, UK (Prof R Bourne MD); Institut de Recherche pour le Développement, Martinique, France (M Boussinesg MD, S Pion PhD); Moorfields Eve Hospital, London, UK (T Braithwaite BMBCh); University of Cambridge, Cambridge, UK (Prof C Brayne MD, K Richardson MSc): University of Leicester, Leicester, UK (ProfTS Brugha MD); Flinders University, Adelaide, SA, Australia (C Bryan-Hancock BPsych, Prof LE Harrison MBBS. L Flood MRRS, T Lathlean MA. Prof K Pesudovs PhD): Cabrini Institute, Malvern, VIC. Australia (Prof R Buchbinder); Department of Epidemiology and Preventive Medicine (B | Gabbe PhD), Monash University, Melbourne, VIC, Australia (Prof R Buchbinder MBBS, D Hoy PhD); Bloomberg School

These sources allow the assessment of the severity distributions taking into account comorbidity (see appendix for more details of this analysis). For some diseases for which data are available for the distribution of severity by age, sex, and region, we pooled proportions in each health state using DisMod-MR or simple meta-analysis methods.

Impairments

For selected impairments, we have constrained the estimates for sequelae related to that impairment to sum to estimates of the impairment prevalence from independent sources of data. For example, nine disorders have blindness

as a sequela. We have analysed all available blindness survey data and we constrain the prevalence of all blindness sequelae to sum to blindness prevalence. We did this impairment prevalence analysis for anaemia, blindness, low vision, hearing impairment, infertility, heart failure, epilepsy, and intellectual disability (appendix).

Analysis of injury burden

The analysis of YLDs from injuries needed careful consideration because injuries are classified in the cause list according to the external cause such as a road injury, animal bite, or drowning, whereas the functional

	Prevalence ((both sexes)	Male prevale	ence	Female prevalence	
	Total (thousands)	Proportion of population (%)	Total (thousands)	Proportion of population (%)	Total (thousands)	Proportion of population (%
Dental caries of permanent teeth	2 431 636	35-29%	1194051	34-37%	1237585	36-23%
Tension-type headache	1431067	20-77%	655 937	18-88%	775 131	22.69%
Migraine	1012944	14-70%	371072	10.68%	641873	18.79%
Fungal skin diseases	985 457	14-30%	516 167	14.86%	469 291	13.74%
Other skin and subcutaneous diseases	803597	11-66%	417129	12.01%	386 468	11.32%
Chronic periodontitis	743 187	10-79%	378 407	10.89%	364780	10.68%
Mild hearing loss with perinatal onset due to other hearing loss	724689	10-52%	386147	11.11%	338 543	9.91%
Acne vulgaris	646488	9-38%	311349	8.96%	335 140	9.81%
Low back pain	632 045	9.17%	334793	9.64%	297252	8.70%
Dental caries of baby teeth	621507	9-02%	352 085	10-13%	269 421	7.89%
Moderate iron-deficiency anaemia	608 915	8-84%	269596	7-76%	339319	9-93%
Other musculoskeletal disorders	560 978	8.14%	262779	7-56%	298199	8-73%
Near sighted due to other vision loss	459646	6-67%	235 052	6-77%	224593	6-58%
Mild iron-deficiency anaemia	375 438	5-45%	152 523	4-39%	222 915	6-53%
Asthma	334247	4.85%	160346	4-61%	173 901	5-09%
Neck pain	332 049	4-82%	135134	3.89%	196 915	5.77%
Chronic obstructive pulmonary disease	328 615	4.77%	168 445	4.85%	160170	4.69%
Genital prolapse	316897	4.55%			316 897	9-28%
Major depressive disorder	298 441	4.33%	111 441	3.21%	187 000	5.48%
Pruritus	280 229	4.07%	117758	3.39%	162 471	4.76%
Anxiety disorders	272777	3.96%	95731	2.76%	177 046	5-18%
Mild anaemia due to hookworm disease	260 254	3.78%	149 572	4.30%	110 681	3-24%
Osteoarthritis of the knee	250785	3.64%	88 885	2-56%	161900	4.74%
Schistosomiasis	238366	3.46%	124289	3-58%	114 077	3-34%
Eczema	229761	3.33%	104259	3.00%	125 502	3-67%
Uncomplicated diabetes mellitus	227588	3.30%	114817	3-30%	112771	3.30%
Uterine fibroids	225 259	3.23%	The same of		225 259	6.60%
Sexually transmitted chlamydial diseases	215 621	3.13%	85 675	2-47%	129 946	3.80%
Benign prostatic hyperplasia	210142	3.05%	210142	6-05%		
Premenstrual syndrome	199 072	2.89%			199 072	5.83%
Moderate hearing loss with perinatal onset due to other hearing loss	189 919	2.76%	103 629	2-98%	86290	2.53%
Goitre due to iodine deficiency	187181	2.72%	69752	2-01%	117 429	3-44%
Lacerations, multiple wounds, other dislocations, and eye injuries due to falls	185700	2-70%	110 263	3.17%	75 438	2.21%
Upper respiratory infections	183137	2-66%	92394	2-66%	90743	2.66%
Lacerations, multiple wounds, other dislocations, and eye injuries due to road injury	180 683	2-62%	118 964	3-42%	61719	1-81%
					(Continue	es on next page

of Public Health (G Buckle MPH.

	Prevalence (both sexes)	Male prevalence		Female prevalence	
	Total (thousands)	Proportion of population (%)	Total (thousands)	Proportion of population (%)	Total (thousands)	Proportion of population (%
(Continued from previous page)						
Edentulism	158 284	2-30%	67264	1.94%	91020	2-66%
Trichomoniasis	152 232	2.21%	49731	1.43%	102501	3-00%
Chronic urolithiasis	144346	2.10%	90 446	2.60%	53 901	1.58%
Mild hearing loss due to otitis media	141600	2-06%	79359	2.28%	62241	1-82%
Mild anaemia due to sickle cell disorders	141 419	2-05%	64343	1.85%	77 075	2-26%
Impetigo	140 495	2-04%	67464	1.94%	73 031	2.14%
Diabetic neuropathy	131 930	1.91%	63509	1.83%	68 421	2.00%
Other cardiovascular and circulatory diseases	127 990	1.86%	48 040	1.38%	79 950	2.34%
Molluscum contagiosum	122 601	1.78%	65841	1.89%	56760	1.66%
Otitis media (chronic)	117881	1.71%	55 891	1.61%	61989	1.81%
Polycystic ovarian syndrome	116730	1.68%			116730	3.42%
Angina due to ischaemic heart disease	111705	1.62%	59683	1.72%	52 022	1.52%
Dysthymia	105 520	1-53%	43 863	1-26%	61657	1.81%
Scabies	100 625	1.46%	51736	1.49%	48 889	1.43%
Mild anaemia due to thalassaemias	95731	1-39%	44362	1.28%	51370	1.50%

limitations after injury are determined by the nature of injury such as brain trauma, femur fracture, or spinal cord transection. We did the injuries analysis in five steps, which are briefly outlined here with further details in the appendix. First, we analysed household survey and hospital discharge data using DisMod-MR for each external cause to generate estimates of incidence by age, sex, country, and year. Survey data included recall of injuries warranting admission to hospital as well as injuries that warranted medical attention but not admission to hospital. The metaregression included a covariate for whether an individual was admitted to hospital or not, which we used to generate predictions both for injury warranting hospital admission and injury warranting outpatient care. Second, we analysed hospital data from 28 countries that had dual coding of discharges by external cause and nature of injury after ICD9 and ICD10, using negative binomial models to estimate the probability of different groups of nature of injury as a function of age, sex, and an indicator variable for developed versus developing countries. Separate models were created for injury warranting hospital admission and injury warranting other health care. Third, for each nature of injury we estimated the probability of individuals developing long-term functional impairment. We re-analysed follow-up data from four studies using data from the Dutch Injury Surveillance system (LIS),80 the South Carolina Traumatic Brain Injury Follow-up Registry (SCTBIFR),81 the National Study on Costs and Outcomes of Trauma (NSCOT),82 and MEPS.77 Fourth, we used DisMod-MR to estimate the prevalence of individuals in the population who are likely to have functional limitation because of a previous injury. Prevalence was estimated from incidence assuming zero remission and a relative risk of death compared with the general population based

on available studies. In the fifth step, the YLDs due to prevalent cases of long-term injury were attributed back to external causes in proportion with the contributions of these causes to every type of injury.

Comorbidity

Comorbidity was taken into account in the calculation of YLDs, which needed three analytical steps (appendix). First, we estimated the co-occurrence of all the sequelae for each age, sex, country, and year. Co-occurrence is a function of the prevalence of each sequela and whether the probabilities of co-occurrence are independent of, or dependent on, each other.83 We could not identify sufficiently large datasets to estimate these dependent probabilities reliably within age groups. We therefore adopted the simplifying assumption of independence. For each age-sex-country-year, we used a Monte Carlo simulation of 20000 individuals to estimate the cooccurrence of sequelae. To capture uncertainty in the prevalences of each of the sequelae, for each age-sexcountry-year, we ran 1000 different micro-simulations of 20 000 individuals.

Second, we calculated the combined disability weight for the estimated individuals with every combination of disorders. For all combinations of disorders generated in the micro-simulation, the combined disability weight for a simulated individual with two or more disorders is one minus the product of one minus each disability weight. Tests on real data such as MEPS as well as other studies suggest that this multiplicative model was the most appropriate. Selection To propagate uncertainty in disability weights into the YLD estimates, each computation was based on a draw from the uncertainty distribution of each disability weight. Third, the combined disability weight

S Maniyannan ScM), Johns Hopkins University, Baltimore, MD. USA (E R Dorsey MD. R Shivakoti BA); Texas A&M University, College Station, TX, USA (C M Budke PhD): Great Ormond Street Hospital. London, UK (M Burch MD): Washington University. St Louis, MO, USA (Prof C E Canter MD): University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA (Prof H Carabin PhD): Telethon Institute for Child Health Research, Centre for Child Health Research (Prof I Carapetis MBBS). University of Western Australia, Perth. WA, Australia (Prof P Norman MD): Universidad Camilo Iose Cela. Villanueva de la Cañada, Spain (L Carmona MD); Mario Negri Institute for Pharmacological Research, Bergamo, Italy (C Cella PharmChemD M Cortinovis BiotechD. F Gaspari ChemD, V Miglioli, N Perico MD. Prof G Remuzzi MD): National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA (H Chen PhD): Institute of Riomedical Sciences Academia Sinica Tainei Taiwan (Prof A T-A Cheng MD): Heart Institute (R Haymoeller MD) Cedars-Sinai Medical Center. Los Angeles, CA, USA (Prof S S Chugh MD); Department of Public Health (S Polinder PhD), Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands (L. E. Coffeng MD. I Haagsma PhD, W A Stolk PhD): Menzies School of Health Research Darwin NT Australia (S Colauhoun MPH. (Condon PhD): National Health Services, Fife, Edinburgh, Scotland, UK (M D Connor PhD): University of Edinburgh, Edinburgh, Scotland, UK (M D Connor, E Fèvre PhD, Prof F G R Fowkes FRCPE): University of the Witwatersrand, Johannesburg, South Africa (M D Connor): Loyola University Medical School, Chicago, IL, USA (Prof LT Cooper MD); School of Public Health Sciences. Wake Forest University, Winston-Salem, NC, USA (M Corriere MD); Hospital Dr Gustavo N Collado.

Puerto Chitre, Panama




Figure 2: Percentage of years lived with disability (YLDs) in 2010, by cause and age
(A) In male individuals. (B) In female individuals. An interactive version of this figure is available online at http://healthmetricsandevaluation.org/qbd/visualizations/regional.

(K Courville de Vaccaro MD): Victorian Infectious Diseases Reference Laboratory. Melbourne, VIC, Australia (B C Cowie MBBS); University of California, San Diego. San Diego, CA, USA (Prof M H Criqui MD. I Denenberg MA): University of Pennsylvania, Philadelphia, PA, USA (N Dahodwala MD, Prof D J Margolis MD); Building and Road Research Institute. Kumasi, Ghana (J Damsere-Derry MPH); MRC Hearing and Communication Group, Manchester, UK (Prof A Davis PhD): School of Dentistry and Oral Health (Prof R Lalloo PhD), Population and Social Health Research Program (Prof R Lalloo), Griffith University, Brisbane, OLD, Australia (Prof D De Leo DSc. N I C Stapelberg MBBS): Denver VA Medical Center, Denver, CO. USA (R Dellavalle MD): University of Otago, Dunedin, New Zealand (S Derrett PhD. R Grainger PhD, T R Merriman PhD. W I Taylor PhD. Prof W M Thomson PhD): Beth Israel Medical Center, New York

from the co-occurrence of sequelae was apportioned to each of the contributing sequelae in proportion to the disability weight of a sequela on its own.

We tested the validity of our assumption of independence within an age-sex-country-year using the MEPS data (described above), which includes both individual-level measurement of functional status using SF-12 and ICD-coded diagnoses. We applied the GBD approach assuming multiplicative disability weights and independent disorder probabilities to estimate YLDs and we computed directly from the MEPS data taking into account actual comorbid patterns at the individual level. The correlation coefficient for the two approaches was 0.999.

YLDs from residual categories

There are nine causes on the cause list such as other neglected tropical diseases, other neurological disorders, or other congenital anomalies that are groupings of a large number of often rare disorders. We approximate the YLDs for these disorders using the ratio of YLDs to YLLs for similar or related disorders to then estimate YLDs for these residual categories from YLLs that have been directly estimated.⁶⁸

Ranking lists

City, NY, USA

(D C Des Jarlais PhD); University of Peradeniya, Peradeniya, For the presentation of leading causes of YLDs, the level at which causes are ranked is subject to debate. We have opted to use the level of disaggregation that seems most relevant for public health decision making. For example, we have chosen to include diarrhoeal diseases, lower respiratory infections, maternal disorders, stroke, liver cancer, cirrhosis, drug use, road injury, exposure to mechanical forces, animal contact, interpersonal violence, and congenital anomalies in the ranking list.

Decomposing changes in YLDs into demographic and epidemiological factors

To help understand the drivers of change in the number of YLDs by cause or region, we have estimated the proportion of the change from 1990 to 2010 due to growth in total population, change in population age-structure and sexstructure, and change in age-specific and sex-specific rates. We computed two counterfactual sets of YLDs. First, a population growth scenario computed as the number of YLDs expected in 2010 if only total population numbers increased to the level of 2010 but the age-sex structure of population stayed the same as in 1990 and age-sex specific rates remained at 1990 levels. Second, a population growth and population ageing scenario computed as the number of YLDs expected in 2010, using 1990 age-specific and sex-specific rates and 2010 age-specific and sexspecific population numbers. The difference between 1990 numbers and the population growth scenario is the change in YLDs due strictly to the growth in total population. The change from the population growth scenario to the population growth and ageing scenario is the number of YLDs due to ageing of the population. The difference between 2010 YLDs and the population growth

	All ages YLDs (thousands)			YLDs (per 100 000)		
	1990	2010	%∆	1990	2010	%∆
All causes	583393 (484649-694406)	777 401 (648 158-921711)	33-3%	11 004 (9142-13 098)	11283 (9407-13378)	2.5%
communicable, maternal, neonatal, and nutritional lisorders	113 925 (85 875-148 463)	119 164 (91 399-152 096)	4.6%	2149 (1620-2800)	1730 (1327-2207)	-19.5%
HIV/AIDS and tuberculosis	7681 (5222-10722)	11 117 (7718-15 187)	44.7%	145 (99-202)	161 (112-220)	11.49
Tuberculosis	6085 (4020-8737)	6774 (4500-9756)	11-3%	115 (76-165)	98 (65-142)	-14-39
HIV/AIDS	1596 (1132-2125)	4342 (3142-5629)	172-2%	30 (21-40)	63 (46-82)	109-4
HIV disease resulting in mycobacterial infection	220 (143-314)	1224 (793-1746)	456-8%	4 (3-6)	18 (12-25)	328-49
HIV disease resulting in other specified or unspecified diseases	1376 (967–1857)	3119 (2241-4107)	126.7%	26 (18-35)	45 (33-60)	74-49
HIV pre-AIDS asymptomatic	376 (227-569)	889 (546-1338)	136.8%	7 (4-11)	13 (8-19)	82-29
HIV pre-AIDS symptomatic	289 (193-411)	531 (350-756)	83-6%	5 (4-8)	8 (5-11)	41.39
AIDS with antiretroviral treatment	0 (0-0)	389 (251-578)		0 (0-0)	6 (4-8)	
AIDS without antiretroviral treatment	711 (483-958)	1309 (913-1758)	84.2%	13 (9-18)	19 (13-26)	41.79
Diarrhoea, lower respiratory infections, meningitis, and other common infectious diseases	18 579 (13 419-25 301)	19 921 (14 241-27 439)	7-2%	350 (253-477)	289 (207–398)	-17-5
Diarrhoeal diseases	7654 (5135-10855)	8045 (5371-11366)	5.1%	144 (97-205)	117 (78-165)	-19-19
Cholera	115 (59-188)	80 (42–134)	-30.1%	2 (1-4)	1 (1-2)	-46-2
Other salmonella infections	263 (150-410)	341 (202–523)	29.8%	5 (3-8)	5 (3-8)	-0.1
Shigellosis	703 (391–1111)	744 (440–1147)	5.8%	13 (7-21)	11 (6-17)	-18-6
Enteropathogenic <i>E coli</i> infection	972 (438–1652)	845 (387–1416)	-13-0%	18 (8-31)	12 (6-21)	-33-1
Enterotoxigenic E coli infection	889 (520–1409)	1065 (649-1643)	19.8%	17 (10–27)	15 (9-24)	-7.8
Campylobacter enteritis	753 (407–1211)	746 (416–1180)	-1-0%	14 (8-23)	11 (6-17)	-23.8
Campylobacter enteritis	753 (406–1211)	746 (415–1181)	-0-9%	14 (8–23)	11 (6-17)	-23.8
Guillain-Barré syndrome due to C enteritis	1 (0-1)	1 (1-2)	35-7%	<0.5 (0-0.5)	<0.5 (0-0.5)	4.4
Amoebiasis	142 (84–217)	205 (126-314)	44.1%	3 (2-4)	3 (2-5)	10.9
Cryptosporidiosis	651 (312–1101)	661 (316–1096)	1.6%	12 (6-21)	10 (5–16)	-21.8
Rotaviral enteritis	1159 (624-1885)	1269 (701–2006)	9.5%	22 (12–36)	18 (10-29)	-15.8
Other diarrhoeal diseases	2007 (1027–3412)	2089 (1054–3521)	4.1%	38 (19-64)	30 (15-51)	-19-9
Typhoid and paratyphoid fevers	134 (25-348)	172 (33-435)	27.8%	3 (0-7)	2 (0-6)	-1.7
Typhoid and paratyphoid fevers	124 (16–337)	159 (20-423)	27.8%	2 (0-6)	2 (0-6)	-1.6
Liver abscess and cysts due to typhoid and paratyphoid fevers	10 (7-15)	13 (8-20)	27.4%	<0.5 (0-0.5)	<0.5 (0-0.5)	-1.9
Lower respiratory infections	2113 (1444-2941)	2331 (1592-3240)	10-3%	40 (27-55)	34 (23-47)	-15-1
Influenza	510 (344-714)	583 (393-815)	14-2%	10 (6-13)	8 (6-12)	-12-1
Influenza	510 (343-713)	582 (392–814)	14.2%	10 (6-13)	8 (6-12)	-12-1
Guillain-Barré syndrome due to influenza	1 (1-2)	2 (1–3)	34-3%	<0.5 (0-0.5)	<0.5 (0-0.5)	3.3
Pneumococcal pneumonia	298 (203-414)	367 (248–509)	23-2%	6 (4-8)	5 (4-7)	-5.2
H influenzae type B pneumonia	216 (145–306)	201 (134–286)	-6.6%	4 (3-6)	3 (2-4)	-28-2
Respiratory syncytial virus pneumonia	52 (31–82)	36 (21–55)	-31-3%	1 (1-2)	1 (0-1)	-47-2
Other lower respiratory infections	1037 (702–1459)	1144 (779–1589)	10.2%	20 (13–28)	17 (11-23)	-15-2
		1728 (911–3050)	20-2%	27 (14–48)	25 (13-44)	-7.5
Upper respiratory infections	1438 (755-2542)	1727 (910–3048)	20.2%	27 (14–48)	25 (13-44)	-7-5
Upper respiratory infections Guillain-Barré syndrome due to upper respiratory infections	1437 (753-2541) 1 (1-2)	2 (1-3)	33.8%	<0.5 (0-0.5)	<0.5 (0-0.5)	3.0
Otitis media	3794 (2456-5829)	4436 (2887-6668)	16.9%	72 (46–110)	64 (42-97)	-10-0
Otitis media Otitis media	1359 (819-2150)	1613 (979-2594)	18.7%	26 (15-41)	23 (14–38)	-8.7
Hearing loss due to otitis media	2435 (1423-3929)	2824 (1669–4533)	16.0%	46 (27-74)	41 (24-66)	-10.8
	2757 (1973–3732)	2628 (1857–3643)	-4.7%	52 (37–70)	38 (27-53)	-26.7
Meningitis Proumococcal meningitis	920 (624–1298)	886 (595–1254)	-3.7%	17 (12–24)	13 (9–18)	-25.9
Pneumococcal meningitis	9 (5-14)	11 (6-17)	19.6%	<0.5 (0-0.5)	<0.5 (0-0.5)	-8.0
S pneumoniae meningitis		488 (261–806)	-14.5%	11 (6-17)	7 (4-12)	-34-2
Long term sequelae due to S pneumoniae meningitis						-34.2
Seizures due to S pneumoniae meningitis	80 (52–118)	79 (55–113)	-0.4%	2 (1–2)	1 (1-2)	n next p

	All ages YLDs (thousands)			YLDs (per 100 000)		
	1990	2010	%∆	1990	2010	%∆
Continued from previous page)						
Hearing loss due to S pneumoniae meningitis	261 (154-420)	308 (185-500)	18-2%	5 (3-8)	4 (3-7)	-9.09
H influenzae type B meningitis	646 (429-933)	371 (247-524)	-42.6%	12 (8-18)	5 (4-8)	-55-8
Hinfluenzae type B meningitis	10 (6-17)	7 (4-12)	-32-0%	<0.5 (0-0.5)	<0.5 (0-0.5)	-47-7
Long term sequelae due to Hinfluenzae type B meningitis	448 (253-715)	233 (124–368)	-48-1%	8 (5-13)	3 (2-5)	-60.0
Seizures due to Hinfluenzae type B meningitis	65 (38-110)	31 (18-51)	-52-2%	1 (1-2)	<0.5 (0-1)	-63.3
Hearing loss due to Hinfluenzae type B meningitis	123 (74-198)	100 (60-160)	-18-5%	2 (1-4)	1 (1-2)	-37-3
Meningococcal infection	424 (302-597)	403 (281-566)	-4.8%	8 (6-11)	6 (4-8)	-26.7
Meningococcal infection	6 (4-10)	7 (4-12)	13.0%	<0.5 (0-0.5)	<0.5 (0-0.5)	-13-0
Long term sequelae due to meningococcal infection	195 (115-306)	165 (92-269)	-15.2%	4 (2-6)	2 (1-4)	-34-8
Seizures due to meningococcal infection	35 (23-52)	28 (18-40)	-21.4%	1 (0-1)	<0.5 (0-1)	-39-5
Hearing loss due to meningococcal infection	187 (110-297)	203 (119–325)	8-6%	4 (2-6)	3 (2-5)	-16.5
Other meningitis	733 (509–1036)	930 (647-1361)	27.0%	14 (10–20)	14 (9-20)	-2.3
Other meningitis	37 (24–53)	49 (31-72)	34-4%	1 (0-1)	1 (0-1)	3.4
Long term sequelae due to other bacterial meningitis infection	283 (157-446)	289 (149–476)	2-2%	5 (3-8)	4 (2-7)	-21.4
Seizures due to other bacterial meningitis infection	48 (32-71)	46 (31-66)	-4-0%	1 (1-1)	1 (0-1)	-26-1
Hearing loss due to other bacterial meningitis infection	365 (221–572)	546 (322–883)	49-6%	7 (4-11)	8 (5-13)	15-1
Encephalitis	183 (120-260)	205 (133-292)	12.6%	3 (2-5)	3 (2-4)	-13-4
Encephalitis	5 (3-9)	7 (4-12)	35.7%	<0.5 (0-0.5)	<0.5 (0-0.5)	4.4
Motor cognitive impairments due to encephalitis	177 (117-253)	198 (128-283)	11.9%	3 (2-5)	3 (2-4)	-13.9
Diphtheria	<0.5 (0-2)	<0.5 (0-1)	-49.1%	<0.5 (0-0.5)	<0.5 (0-0.5)	-60.9
Whooping cough	181 (103–287)	122 (70–195)	-32-5%	3 (2-5)	2 (1–3)	-48.0
Tetanus	78 (35–159)	21 (9-43)	-72-3%	1 (1-3)	<0.5 (0-1)	-78-7
Tetanus	77 (35-158)	21 (9-43)	-72-3%	1 (1-3)	<0.5 (0-1)	-78-7
Long-term sequelae from neonatal tetanus	1 (0-2)	<0.5 (0-1)	-73.2%	<0.5 (0-0.5)	<0.5 (0-0.5)	-79-4
Measles	106 (58–180)	31 (17–51)	-70.8%	2 (1–3)		
Varicella	142 (87–219)	202 (124–308)	42.0%		<0.5 (0-1)	-77-5
Chickenpox	7 (2–16)	7 (2–16)	-0.9%	3 (2-4) <0·5 (0-0·5)	3 (2-4)	9·3' -23·8'
Herpes zoster	135 (84-209)	195 (120-295)	44.3%		<0.5 (0-0.5)	11.09
Neglected tropical diseases and malaria	23 491 (15715–36 639)	22 219 (15 693-31 544)	-5.4%	3 (2-4) 443 (296-691)	3 (2-4) 322 (228-458)	-27-29
Malaria	2662 (1257-4481)	4070 (1853-6980)	52.9%	50 (24-85)	59 (27–101)	17.79
Malaria	433 (194-854)	498 (218-933)	14.8%	8 (4-16)		-11.69
Anaemia due to malaria	2127 (833-3972)	3367 (1312-6294)	58.3%	40 (16-75)	7 (3–14)	21.89
Motor cognitive impairments due to malaria	104 (41-273)	211 (81-556)	102.8%	2 (1-5)	49 (19–91) 3 (1–8)	56.09
Chagas disease	324 (108-594)	303 (106-573)	-6.4%	6 (2-11)	4 (2-8)	-28.09
Acute Chagas disease	31 (7-62)	28 (7–59)	-8.8%	1 (0-1)	<0.5 (0-1)	-29-89
Chronic heart disease due to Chagas disease	213 (38-429)	195 (36-411)	-8.4%			
Chronic digestive disease due to Chagas disease	73 (8–178)	67 (7–157)	-8-5%	4 (1-8)	3 (1-6)	-29.59
Heart failure due to Chagas disease				1 (0-3) <0.5 (0-0.5)	1 (0-2)	-29.69
Leishmaniasis	7 (4-10) 113 (53-215)	13 (8-19) 124 (60-235)	92.6%		<0.5 (0-0.5)	48-29
Visceral leishmaniasis	8 (2–16)		10-2%	2 (1-4)	2 (1-3)	-15-29
Cutaneous leishmaniasis		6 (2-13)	-17-2%	<0.5 (0-0.5)	<0.5 (0-0.5)	-36-39
African trypanosomiasis	105 (47–206)	118 (56–229)	12.2%	2 (1-4)	2 (1–3)	-13-79
Schistosomiasis	33 (12-86)	8 (2-25)	-75.2%	1 (0-2)	<0.5 (0-0.5)	-80-99
Schistosomiasis Schistosomiasis	1797 (923-3413)	2986 (1541–5666)	66.2%	34 (17-64)	43 (22-82)	27-99
	696 (229–1579)	1148 (377–2607)	65-0%	13 (4-30)	17 (5–38)	27-09
Mild diarrhoea due to schistosomiasis	1 (0-1)	1 (1-2)	77-2%	<0.5 (0-0.5)	<0.5 (0-0.5)	36-39
Anaemia due to schistosomiasis	433 (219–766)	687 (344-1217)	58-8%	8 (4-14)	10 (5–18)	22-29
Hepatomegaly due to schistosomiasis	104 (47-200)	185 (84-355)	77-8%	2 (1-4)	3 (1-5)	36-89
Haematemesis due to schistosomiasis	39 (26–55)	69 (46-97)	76-6%	1 (0-1)	1 (1-1)	35.99
					(Continues o	on next pa

	All ages YLDs (thousands)			YLDs (per 100 000)		
	1990	2010	%∆	1990	2010	%∆
Continued from previous page)						
Ascites due to schistosomiasis	31 (21-44)	56 (38-77)	78.9%	1 (0-1)	1 (1-1)	37-79
Dysuria due to schistosomiasis	174 (80-334)	298 (135-572)	71.0%	3 (2-6)	4 (2-8)	31.59
Bladder pathology due to schistosomiasis	159 (72-304)	268 (122-515)	68-9%	3 (1-6)	4 (2-7)	30.09
Hydronephrosis due to schistosomiasis	162 (74-310)	277 (126-533)	71-5%	3 (1-6)	4 (2-8)	32.09
Cysticercosis	484 (378-600)	457 (357-566)	-5.5%	9 (7-11)	7 (5-8)	-27.3
Echinococcosis	89 (44-187)	110 (55-228)	23-9%	2 (1-4)	2 (1-3)	-4.79
Chronic respiratory disease due to echinococcosis	2 (1-6)	3 (1-7)	22.8%	<0.5 (0-0.5)	<0.5 (0-0.5)	-5.5
Epilepsy due to echinococcosis	13 (6-28)	16 (8-32)	24-1%	<0.5 (0-1)	<0.5 (0-0.5)	-4.5
Abdominopelvic problems due to echinococcosis	73 (36-155)	91 (43-193)	23-9%	1 (1-3)	1 (1-3)	-4.7
Lymphatic filariasis	2368 (1551-3399)	2775 (1807-4000)	17-2%	45 (29-64)	40 (26-58)	-9.9
Lymphoedema	955 (585-1454)	1151 (698-1773)	20-5%	18 (11-27)	17 (10-26)	-7:3
Hydrocele due to lymphatic filariasis	1414 (842-2103)	1624 (981-2450)	14-9%	27 (16-40)	24 (14-36)	-11.6
Onchocerciasis	512 (361-687)	494 (360-656)	-3-5%	10 (7-13)	7 (5-10)	-25.7
Skin disease due to onchocerciasis	407 (277-559)	352 (240-486)	-13-3%	8 (5-11)	5 (3-7)	-33-3
Vision loss due to onchocerciasis	105 (79-134)	142 (108-185)	34-5%	2 (1-3)	2 (2-3)	3-5
Trachoma	144 (104-189)	334 (243-438)	132.5%	3 (2-4)	5 (4-6)	78-9
Dengue	6 (2-13)	12 (6-23)	103.9%	<0.5 (0-0.5)	<0.5 (0-0.5)	56-9
Dengue	5 (2-11)	10 (5-20)	105-9%	<0.5 (0-0.5)	<0.5 (0-0.5)	58-5
Post-dengue chronic fatigue syndrome	1 (0-2)	2 (0-4)	92.6%	<0.5 (0-0.5)	<0.5 (0-0.5)	48-2
Yellow fever	<0.5 (0-0.5)	<0.5 (0-0.5)	15.1%	<0.5 (0-0.5)	<0.5 (0-0.5)	-11-4
Rabies	<0.5 (0-1)	<0.5 (0-1)	-56-7%	<0.5 (0-0.5)	<0.5 (0-0.5)	-66-7
Intestinal nematode infections	8741 (4778-15094)	4980 (2722-8442)	-43-0%	165 (90-285)	72 (40-123)	-56-2
Ascariasis	3950 (2080-6805)	1111 (618-1864)	-71-9%	75 (39-128)	16 (9-27)	-78-4
Ascariasis infestation	1995 (1091–3254)	758 (419–1232)	-62-0%	38 (21-61)	11 (6-18)	-70-8
Severe wasting due to ascariasis	49 (32-72)	43 (28-62)	-12-8%	1 (1-1)	1 (0-1)	-32-9
Mild abdominopelvic problems due to ascariasis	1906 (871-3673)	310 (139-598)	-83-7%	36 (16-69)	4 (2-9)	-87-5
Trichuriasis	857 (465–1420)	638 (349-1061)	-25-5%	16 (9-27)	9 (5-15)	-42-7
Trichuriasis infestation	677 (367–1104)	504 (277-821)	-25.6%	13 (7-21)	7 (4–12)	-42.8
Severe wasting due to trichuriasis	9 (5-13)	9 (5-13)	-0.5%	<0.5 (0-0.5)	<0.5 (0-0.5)	-23-4
Mild abdominopelvic problems due to trichuriasis	171 (77–327)	126 (57-246)	-26-3%	3 (1-6)	2 (1–4)	-43-3
Hookworm disease	3934 (2056-6983)	3231 (1695-5732)	-17-9%	74 (39-132)	47 (25-83)	-36-8
Hookworm infestation	1315 (718-2150)	1011 (556-1655)	-23.1%	25 (14-41)	15 (8-24)	-40-9
Severe wasting due to hookworm disease	34 (21-49)	42 (27-61)	23.4%	1 (0-1)	1 (0-1)	-5-0
Mild abdominopelvic problems due to hookworm disease	241 (110-462)	217 (98-422)	-10.0%	5 (2-9)	3 (1-6)	-30-8
Anaemia due to hookworm disease	2344 (983-4348)	1962 (895-3672)	-16-3%	44 (19-82)	28 (13-53)	-35-6
Food-borne trematodiases	2394 (635-8501)	1875 (708-4837)	-21.7%	45 (12-160)	27 (10-70)	-39-7
Heavy clonorchiasis	367 (95-1145)	296 (100-822)	-19-4%	7 (2-22)	4 (1-12)	-37-9
Heavy fascioliasis	32 (18-53)	42 (26-65)	32-5%	1 (0-1)	1 (0-1)	2.0
Heavy intestinal fluke infection	101 (58-179)	106 (64-170)	4-9%	2 (1-3)	2 (1-2)	-19-3
Heavy opisthorchiasis	48 (29-77)	60 (37-92)	27-0%	1 (1-1)	1 (1-1)	-2-3
Cerebral paragonimiasis	57 (7-245)	43 (8-148)	-25-2%	1 (0-5)	1 (0-2)	-42-4
Heavy paragonimiasis	1789 (233-7696)	1328 (280-4234)	-25.8%	34 (4-145)	19 (4-61)	-42.9
Other neglected tropical diseases	3825 (2517-6057)	3690 (2556-5303)	-3.5%	72 (47-114)	54 (37-77)	-25-8
Other neglected tropical disease	1007 (533-2568)	949 (657–1557)	-5.8%	19 (10-48)	14 (10-23)	-27-5
Anaemia due to other neglected tropical diseases	2873 (1920-4163)	2800 (1857-4054)	-2.5%	54 (36-79)	41 (27-59)	-25-0
Maternal disorders	1394 (935-2271)	1790 (1138–2936)	28-4%	26 (18-43)	26 (17-43)	-1-2
Maternal haemorrhage	143 (84-234)	98 (61–151)	-31.7%	3 (2-4)	1 (1-2)	-47-5
Maternal haemorrhage	29 (18-46)	19 (12-29)	-34.2%	1 (0-1)	<0.5 (0-0.5)	-49-4
2	1-1	-,/		A STATE OF LOTHING WAS A STATE OF	and the other production of the Contract of	s on next p

	All ages YLDs (thousands)			YLDs (per 100 000)		
	1990	2010	%∆	1990	2010	%∆
Continued from previous page)			Valid a			
Anaemia due to maternal haemorrhage	114 (65-193)	79 (47–124)	-31.1%	2 (1-4)	1 (1-2)	-47.09
Maternal sepsis	80 (46-128)	42 (25-65)	-48-4%	2 (1-2)	1 (0-1)	-60.39
Hypertensive disorders of pregnancy	69 (41-111)	93 (53-151)	33.2%	1 (1-2)	1 (1-2)	2.59
Pre-eclampsia	60 (33-100)	83 (44-141)	38-9%	1 (1-2)	1 (1-2)	6.99
Eclampsia	4 (1-7)	3 (1-7)	-14-6%	<0.5 (0-0.5)	<0.5 (0-0.5)	-34-39
Long-term sequelae for hypertensive disorders of pregnancy	6 (1-15)	7 (2-15)	6-3%	<0.5 (0-0.5)	<0.5 (0-0.5)	-18-29
Obstructed labour	809 (458-1493)	1182 (641-2194)	46.0%	15 (9-28)	17 (9-32)	12-4
Obstructed labour	77 (40–140)	34 (19-57)	-56-1%	1 (1-3)	<0.5 (0-1)	-66-39
Fistula	732 (390-1425)	1148 (601-2138)	56-8%	14 (7-27)	17 (9-31)	20-6
Abortion	27 (15-52)	32 (19-59)	19.8%	1 (0-1)	<0.5 (0-1)	-7.8
Other maternal disorders	264 (180-420)	343 (225–526)	30.1%	5 (3-8)	5 (3-8)	0.19
Neonatal disorders	8422 (6368–10706)	9464 (7167-11937)	12.4%	159 (120–202)	137 (104-173)	-13.59
Preterm birth complications	2298 (1743-2895)	2982 (2236–3716)	29.7%	43 (33-55)	43 (32-54)	-0.29
Impairment due to preterm birth complications	2041 (1471–2613)	2636 (1882–3359)	29.1%	39 (28-49)	38 (27-49)	-0.2
Retinopathy of prematurity due to preterm birth complications	257 (154-376)	347 (212–508)	34.9%	5 (3-7)	5 (3-7)	3.8
Neonatal encephalopathy (birth asphyxia/trauma)	5625 (4116-7298)	6132 (4471-8030)	9.0%	106 (78-138)	89 (65-117)	-16-19
Sepsis and other infectious disorders of the newborn baby	18 (9-32)	23 (12-40)	24.9%	<0.5 (0-1)	<0.5 (0-1)	-3.9
Other neonatal disorders	481 (357-618)	328 (244-417)	-31.8%	9 (7-12)	5 (4-6)	-47-59
Nutritional deficiencies	49 887 (34714-70780)	49 942 (34705-70 350)	0.1%	941 (655–1335)	725 (504–1021)	-23.0
Protein-energy malnutrition	3200 (2071-4743)	2720 (1766–3972)	-15.0%	60 (39-89)	39 (26-58)	-34-6
Kwashiokor or marasmus due to protein-energy malnutrition	298 (155–520)	197 (103-339)	-33.7%	6 (3-10)	3 (1–5)	-49-0
Severe wasting due to protein-energy malnutrition	2906 (1803-4418)	2530 (1604-3772)	-12-9%	55 (34-83)	37 (23-55)	-33-0
lodine deficiency	3181 (2049-4912)	3889 (2468-6136)	22.3%	60 (39-93)	56 (36-89)	-5.9
Goitre due to iodine deficiency	2902 (1823-4617)	3767 (2382–5990)	29.8%	55 (34-87)	55 (35-87)	-0.19
Idiopathic intellectual disability due to iodine deficiency	271 (181–386)	113 (73-167)	-58-4%	5 (3-7)	2 (1-2)	-68-0
Heart failure due to iodine deficiency	7 (5-11)	10 (6-14)	33-3%	<0.5 (0-0.5)	<0.5 (0-0.5)	2.69
Vitamin A deficiency	740 (565–941)	806 (612–1037)	9.0%	14 (11–18)	12 (9-15)	-16-19
Iron-deficiency anaemia	42731 (28506-61896)	42 494 (28 170-61 626)	-0.6%	806 (538–1167)	617 (409-894)	-23.59
Iron-deficiency anaemia	42728 (28497-61897)	42505 (28166-61656)	-0.5%	806 (538–1168)	617 (409-895)	-23.59
Heart failure due to iron-deficiency anaemia	17 (11-24)	24 (16–36)	46.7%			
Other nutritional deficiencies	35 (31–44)	32 (24-36)	-9.2%	<0·5 (0-0·5) 1 (1-1)	<0.5 (0-1)	12-99
Other communicable, maternal, neonatal, and nutritional disorders	4472 (3188–6195)	4711 (3352–6562)	5.3%	84 (60-117)	<0·5 (0-1) 68 (49-95)	-30·19 -18·99
Sexually transmitted diseases excluding HIV	1111 (589–2072)	1298 (704-2439)	16-9%	21 (11–39)	19 (10-35)	-10.09
Syphilis	73 (3-156)	91 (4-200)	25.5%	1 (0-3)	1 (0-3)	-3.49
Sexually transmitted chlamydial diseases	560 (268–1025)	669 (324–1233)	19-6%	11 (5-19)	10 (5-18)	-8.09
Sexually transmitted chlamydial diseases	507 (233–952)	609 (281–1143)	20-1%	10 (4-18)	9 (4-17)	-7.69
Salpingitis, inflammatory disease of cervix, and other female pelvic inflammatory diseases due to sexually transmitted chlamydial diseases	27 (16-43)	25 (15–40)	-7.5%	1 (0-1)	<0.5 (0-1)	-28-89
Infertility due to sexually transmitted chlamydial diseases	25 (9–53)	35 (14–72)	37-7%	<0.5 (0-1)	1 (0-1)	6.09
Gonococcal infection	184 (94-336)	249 (123-450)	35-1%	3 (2-6)	4 (2-7)	4.0%
Gonococcal infection	147 (69–282)	207 (96–390)	40.7%	3 (1-5)	3 (1-6)	8.39
Salpingitis, inflammatory disease of cervix, and other female pelvic inflammatory diseases due to gonococcal infection	20 (12–33)	19 (11-31)	-7.7%	<0.5 (0-1)	<0.5 (0-0.5)	-29.09
Infertility due to gonococcal infection	17 (7-35)	23 (9-47)	37.7%	<0.5 (0-1)	<0.5 (0-1)	5.99
				- 1/	/	33"

	All ages YLDs (thousands)			YLDs (per 100 000)		
	1990	2010	%Δ	1990	2010	%∆
(Continued from previous page)						
Trichomoniasis	182 (0-549)	167 (0-493)	-8.4%	3 (0-10)	2 (0-7)	-29.5%
Other sexually transmitted diseases	112 (68-181)	122 (74-200)	9.3%	2 (1-3)	2 (1-3)	-15-9%
Other sexually transmitted diseases	70 (42-111)	64 (39-105)	-7.8%	1 (1-2)	1 (1-2)	-29.0%
Infertility due to other sexually transmitted diseases	42 (17-91)	58 (23-125)	37.7%	1 (0-2)	1 (0-2)	5.9%
Hepatitis	449 (230-810)	542 (280-981)	20.7%	8 (4-15)	8 (4-14)	-7.1%
Acute hepatitis A	172 (85-294)	185 (95-311)	7-6%	3 (2-6)	3 (1-5)	-17-29
Acute hepatitis B	194 (24-456)	248 (28-585)	28-1%	4 (0-9)	4 (0-8)	-1.49
Acute hepatitis C	24 (4-50)	39 (7-79)	61.2%	<0.5 (0-1)	1 (0-1)	24.19
Acute hepatitis E	59 (20-121)	69 (24-142)	17-8%	1 (0-2)	1 (0-2)	-9.39
Leprosy	26 (12-48)	6 (3-11)	-76-6%	<0.5 (0-1)	<0.5 (0-0.5)	-82-09
Other infectious diseases	2886 (1920-4175)	2864 (1902-4141)	-0.8%	54 (36-79)	42 (28-60)	-23-69
Other infectious diseases	922 (615-1330)	957 (635-1386)	3.8%	17 (12-25)	14 (9-20)	-20-29
Anaemia due to other infectious diseases	2000 (1329-2897)	1947 (1292-2812)	-2.7%	38 (25-55)	28 (19-41)	-25-19
Guillain-Barré syndrome due to other infectious diseases	1 (0-1)	1 (0-1)	35-8%	<0.5 (0-0.5)	<0.5 (0-0.5)	4-59
Ion-communicable diseases	435 400 (365 526 - 515 063)	611076 (512645-721956)	40-3%	8213 (6895-9715)	8869 (7440-10478)	8.0
Neoplasms	2540 (1876-3348)	4483 (3324-5861)	76-5%	48 (35-63)	65 (48-85)	35.8
Oesophageal cancer	61 (42-86)	75 (49–103)	22.8%	1 (1-2)	1 (1-1)	-5.59
Stomach cancer	204 (137-286)	229 (150-323)	12-3%	4 (3-5)	3 (2-5)	-13.6
Liver cancer	77 (53-104)	140 (96-189)	82-7%	1 (1-2)	2 (1-3)	40-6
Liver cancer secondary to hepatitis B	35 (23-49)	64 (43-89)	81.4%	1 (0-1)	1 (1-1)	39.6
Liver cancer secondary to hepatitis C	19 (13-27)	34 (23-47)	80.5%	<0.5 (0-1)	<0.5 (0-1)	38.9
Liver cancer secondary to alcohol use	15 (9-21)	29 (19-42)	100-2%	<0.5 (0-0.5)	<0.5 (0-1)	54-19
Other liver cancer	8 (4-12)	12 (7-19)	60-3%	<0.5 (0-0.5)	<0.5 (0-0.5)	23-3
Larynx cancer	47 (26–77)	63 (34–102)	32.5%	1 (0-1)	1 (0-1)	2.0
Trachea, bronchus, and lung cancers	227 (154–317)	355 (234-493)	56-5%	4 (3-6)	5 (3-7)	20.5
Breast cancer	504 (351-714)	898 (623–1268)	78.0%	10 (7-13)	13 (9-18)	37.0
Cervical cancer	99 (59–146)	111 (64-160)	11.8%	2 (1-3)	2 (1-2)	-14.0
Uterine cancer	47 (25–82)	68 (30–107)	44.5%	1 (0-2)	1 (0-2)	11.2
Prostate cancer	165 (109–249)	464 (298-729)	181-3%	3 (2-5)	7 (4-11)	116-4
Colon and rectum cancers	307 (223-411)	564 (408–759)	83.9%	6 (4-8)	8 (6–11)	41.5
Mouth cancer	63 (44-84)	101 (71–136)	61.6%	1 (1-2)	1 (1-2)	24-3
		25 (14-39)	64.1%	<0.5 (0-0.5)	<0.5 (0-1)	26-3
Nasopharynx cancer	15 (9–23) 29 (16–42)	45 (25-67)	53.3%	1 (0-1)	1 (0-1)	18-0
Cancer of other part of pharynx and oropharynx			81.2%	<0.5 (0-1)	1 (0-1)	39.5
Gallbladder and biliary tract cancer	19 (12-29)	35 (20-53)	59.4%	<0.5 (0-1)	1 (0-1)	22.6
Pancreatic cancer	23 (15-33)	37 (23-54) 45 (25-74)	84.5%	<0.5 (0-1)	1 (0-1)	42.0
Malignant melanoma of skin	24 (15-40)		122.2%	2 (2-3)	4 (3-5)	71.0
Non-melanoma skin cancer	115 (85-148)	255 (192–326) 63 (39–89)	53.8%	1 (1-1)	1 (1-1)	18.3
Ovarian cancer	41 (27–56)	12 (7–20)		<0.5 (0-0.5)	<0.5 (0-0.5)	26.4
Testicular cancer	8 (4-12)		64-2%			87-3
Kidney and other urinary organ cancers	32 (21-48)	79 (52-118)	143-4%	1 (0-1)	1 (1-2) 2 (1-2)	18-9
Bladder cancer	81 (57–110)	125 (85–171)	54-6%	2 (1–2)		25.6
Brain and nervous system cancers	57 (34-84)	94 (51-134)	63-3%	1 (1-2)	1 (1-2)	78-8
Thyroid cancer	21 (13-32)	48 (28-75)	132-4%	<0.5 (0-1)	1 (0-1)	
Hodgkin's disease	13 (8-20)	17 (10-27)	25.7%	<0.5 (0-0.5)	<0.5 (0-0.5)	-3-3
Non-Hodgkin's lymphoma	60 (42–80)	110 (77-147)	83.5%	1 (1-2)	2 (1-2)	41.2
Multiple myeloma	22 (13–34)	36 (21-53)	64.9%	<0.5 (0-1)	1 (0-1)	26.9
Leukaemia	79 (53–110)	123 (83–170)	57-2%	1 (1-2)	2 (1-2)	20.9
Other neoplasms	99 (67–139)	266 (174–366)	168-2%	2 (1-3)	4 (3-5)	106-4
Cardiovascular and circulatory diseases	14373 (11094-18134)	21 985 (16 947-27 516)	53-0%	271 (209–342)	319 (246–399)	17-7
Rheumatic heart disease	1150 (765-1709)	1430 (944-2067)	24.3%	22 (14-32)	21 (14-30)	-4-4

	All ages YLDs (thousands)			YLDs (per 100 000)		BASSE!
	1990	2010	%∆	1990	2010	%∆
Continued from previous page)			PATE NAME OF			e-miles
Valvular disease due to rheumatic heart disease	861 (477-1429)	1009 (557-1646)	17.3%	16 (9-27)	15 (8-24)	-9-89
Heart failure due to rheumatic heart disease	290 (191-412)	420 (278-592)	45.1%	5 (4-8)	6 (4-9)	11.6
Ischaemic heart disease	5952 (3679-8768)	8795 (5447-12806)	47.8%	112 (69-165)	128 (79-186)	13.79
Myocardial infarction due to ischaemic heart disease	29 (15-45)	42 (22-67)	45.5%	1 (0-1)	1 (0-1)	11.9
Angina due to ischaemic heart disease	5030 (2942-7567)	7234 (4232-10 986)	43.8%	95 (55-143)	105 (61-159)	10-79
Heart failure due to ischaemic heart disease	894 (609-1236)	1518 (1038-2128)	69-9%	17 (11-23)	22 (15-31)	30-8
Cerebrovascular disease	2328 (1864-2837)	4346 (3476-5298)	86-7%	44 (35-54)	63 (50-77)	43.6
Ischaemic stroke	1857 (1489-2263)	3384 (2705-4121)	82.2%	35 (28-43)	49 (39-60)	40-2
Ischaemic stroke (acute)	77 (52–107)	133 (90-183)	72.8%	1 (1-2)	2 (1-3)	32.9
Ischaemic stroke (chronic)	1780 (1416-2187)	3251 (2583-3999)	82-6%	34 (27-41)	47 (37-58)	40.5
Haemorrhagic and other non-ischaemic stroke	471 (373-585)	961 (769-1178)	104.1%	9 (7-11)	14 (11-17)	57-0
Haemorrhagic non-ischaemic stroke (acute)	28 (18-38)	56 (37-78)	104.1%	1 (0-1)	1 (1-1)	57-19
Haemorrhagic non-ischaemic stroke (chronic)	444 (345-558)	905 (717-1121)	104-1%	8 (7-11)	13 (10-16)	57-0
Hypertensive heart disease	292 (202-412)	460 (315-639)	57-4%	6 (4-8)	7 (5-9)	21-19
Cardiomyopathy and myocarditis	272 (183-378)	394 (269-551)	44-8%	5 (3-7)	6 (4-8)	11-4
Acute myocarditis	1 (0-1)	1 (0-1)	30-9%	<0.5 (0-0.5)	<0.5 (0-0.5)	0.79
Heart failure due to cardiomyopathy and myocarditis	271 (182–378)	393 (268–551)	44-8%	5 (3-7)	6 (4-8)	11-4
Atrial fibrillation and flutter	1433 (970-1987)	2425 (1631-3382)	69.2%	27 (18-37)	35 (24-49)	30-29
Peripheral vascular disease	256 (132-453)	419 (218-744)	63.7%	5 (2-9)	6 (3-11)	26.0
Endocarditis	42 (28-60)	62 (42-87)	46.1%	1 (1-1)	1 (1-1)	12-4
Endocarditis	<0.5 (0-1)	1 (0-1)	87-7%	<0.5 (0-0.5)	<0.5 (0-0.5)	44-4
Heart failure due to endocarditis	42 (28-59)	61 (42-87)	45-8%	1 (1-1)	1 (1-1)	12-29
Other cardiovascular and circulatory diseases	2646 (1448-4148)	3655 (2053-5581)	38-1%	50 (27–78)	53 (30-81)	6.39
Heart failure due to other circulatory diseases	183 (123-259)	268 (180–372)	46-3%	3 (2-5)	4 (3-5)	12.6
Other cardiovascular and circulatory diseases	2463 (1271–3992)	3388 (1783-5346)	37.5%	46 (24-75)	49 (26–78)	5.8
Chronic respiratory diseases	34976 (24536-47579)	49 303 (33 874-67 087)	41.0%	660 (463-897)	716 (492–974)	8.5
Chronic obstructive pulmonary disease	20 097 (13 793-28 248)	29373 (19850-41822)	46.2%	379 (260-533)	426 (288-607)	12.59
Chronic obstructive pulmonary disease	19805 (13571-27835)	28 893 (19 455-41 183)	45.9%	374 (256–525)	419 (282–598)	12.39
Heart failure due to chronic obstructive pulmonary disease	292 (195–410)	480 (316-678)	64.1%	6 (4-8)	7 (5–10)	26-39
Pneumoconiosis	212 (104-477)	445 (193-1377)	109-9%	4 (2-9)	6 (3-20)	61-59
Silicosis	76 (22–199)	136 (38-408)	79.8%	1 (0-4)	2 (1-6)	38-39
Asbestosis	44 (4-253)	130 (8–974)	192.4%	1 (0-5)	2 (0-14)	125.09
Coal workers' pneumoconiosis	24 (10-43)	33 (13-64)	41.1%	<0.5 (0-1)	<0.5 (0-1)	8.69
Other pneumoconiosis	43 (12–108)	101 (26–261)	135.2%	1 (0-2)	1 (0-4)	80.99
Heart failure due to pneumoconiosis	25 (17–36)	45 (31-63)	77.1%	<0.5 (0-1)	1 (0-1)	36-39
Asthma	10 835 (7247-15 268)	13 835 (9286-19 487)	27-7%	204 (137–288)	201 (135–283)	-1.79
Interstitial lung disease and pulmonary sarcoidosis	111 (68–182)	162 (99–268)	45-8%	2 (1-3)	2 (1-4)	12.29
Interstitial lung disease and pulmonary sarcoidosis	69 (37–134)	99 (52–191)	44-6%	1 (1-3)	1 (1-3)	11.39
Heart failure due to interstitial lung disease and pulmonary sarcoidosis	42 (28–60)	62 (42–90)	47-9%	1 (1-1)	1 (1-1)	13.89
Other chronic respiratory diseases	3722 (2529-5177)	5488 (3773-7675)	47.5%	70 (48-98)	80 (55-111)	13.59
Cirrhosis of the liver	455 (309-630)	613 (415–862)	34.8%	9 (6-12)	9 (6-13)	3.7%
Cirrhosis of the liver secondary to hepatitis B	156 (93-235)	198 (120–298)	26.7%	3 (2-4)	3 (2-4)	-2.5%
Cirrhosis of the liver secondary to hepatitis C	113 (67–170)	155 (93-235)	37.5%	2 (1-3)	2 (1-3)	5.89
Cirrhosis of the liver secondary to alcohol use	109 (65–163)	160 (94-241)	46.6%	2 (1-3)	2 (1-3)	12.89
Other cirrhosis of the liver	77 (46–118)	101 (61–150)	30.2%	1 (1-2)	1 (1-2)	0.2%
Digestive diseases (except cirrhosis)	4467 (3265-5979)	5473 (3916–7380)	22.5%	84 (62–113)	79 (57-107)	-5.7%
Peptic ulcer disease	355 (224-570)	311 (196-485)	-12.3%	7 (4-11)		
Peptic ulcer disease	190 (111–328)	154 (93-254)	-12.3%	4 (2-6)	5 (3-7) 2 (1-4)	-32-5% -37-5%
	4JV (444]4U/			44 LZ=() 1	Z 1 1 = 41	-5/-5%

	All ages YLDs (thousands)			YLDs (per 100 000)		
	1990	2010	%∆	1990	2010	%Δ
Continued from previous page)						
Anaemia due to peptic ulcer disease	165 (89-325)	157 (87-273)	-4-8%	3 (2-6)	2 (1-4)	-26.7%
Gastritis and duodenitis	820 (498-1253)	855 (525-1386)	4-2%	15 (9-24)	12 (8-20)	-19.8%
Gastritis and duodenitis	178 (120-259)	182 (121-264)	2-3%	3 (2-5)	3 (2-4)	-21.3%
Anaemia due to gastritis and duodenitis	642 (368-1046)	673 (389-1174)	4.7%	12 (7-20)	10 (6-17)	-19-49
Appendicitis	154 (99-226)	176 (112-257)	14.3%	3 (2-4)	3 (2-4)	-12.09
Paralytic ileus and intestinal obstruction without hernia	10 (4-24)	12 (6-27)	24-4%	<0.5 (0-0.5)	<0.5 (0-0.5)	-4.29
Inguinal or femoral hernia	333 (144-689)	441 (189-861)	32-5%	6 (3-13)	6 (3-12)	1.99
Non-infective inflammatory bowel disease	1582 (1130-2151)	1795 (1272-2460)	13.5%	30 (21-41)	26 (18-36)	-12.79
Non-infective inflammatory bowel disease due to ulcerative colitis	932 (583–1492)	1169 (734-1801)	25-4%	18 (11-28)	17 (11–26)	-3.59
Non-infective inflammatory bowel disease due to Crohn's disease	541 (356-775)	513 (334-733)	-5-2%	10 (7-15)	7 (5–11)	-27-09
Non-infective inflammatory bowel disease severe episodes due to ulcerative colitis	54 (32–89)	64 (39–102)	18-6%	1 (1-2)	1 (1-1)	-8-79
Non-infective inflammatory bowel disease severe episodes due to Crohn's disease	54 (31-91)	50 (30-81)	-8-5%	1 (1-2)	1 (0-1)	-29-69
Vascular disorders of intestine	6 (4-10)	14 (8-20)	121.6%	<0.5 (0-0.5)	<0.5 (0-0.5)	70.59
Gallbladder and bile duct disease	314 (215-440)	453 (310-635)	44-6%	6 (4-8)	7 (4-9)	11.29
Pancreatitis	133 (85-198)	206 (131-303)	54.9%	3 (2-4)	3 (2-4)	19-29
Other digestive diseases	761 (553-1025)	1209 (852-1638)	58.9%	14 (10-19)	18 (12-24)	22.3
Neurological disorders	29 389 (23 635-35 837)	42 943 (34 605-52 115)	46.1%	554 (446-676)	623 (502-756)	12-4
Alzheimer's disease and other dementias	3785 (2720-5007)	6801 (4898-9043)	79.7%	71 (51-94)	99 (71-131)	38-3
Parkinson's disease	356 (231-560)	606 (396-964)	70.5%	7 (4-11)	9 (6-14)	31-2
Epilepsy	6415 (4993-7799)	8740 (6762-10594)	36.2%	121 (94-147)	127 (98-154)	4.8
Multiple sclerosis	373 (276-473)	524 (379-660)	40.8%	7 (5-9)	8 (5-10)	8-3
Migraine	15 927 (10 394-22 023)	22362 (14395-31121)	40-4%	300 (196-415)	325 (209-452)	8-0
Tension-type headache	1266 (754-2016)	1779 (1056-2822)	40.5%	24 (14-38)	26 (15-41)	8.1
Other neurological disorders	1267 (958-1616)	2129 (1619-2723)	68-0%	24 (18-30)	31 (23-40)	29-3
Other neurological disorders	1399 (1056-1789)	2353 (1785-3011)	68-2%	26 (20-34)	34 (26-44)	29.4
Guillain-Barré syndrome due to other neurological disorders	2 (1–3)	3 (2-4)	35-6%	<0.5 (0-0.5)	<0.5 (0-0.5)	4.4
Mental and behavioural disorders	129 377 (106 771-154 032)	176 626 (145 613-209 122)	36.5%	2440 (2014-2905)	2564 (2113-3035)	5.0
Schizophrenia	9760 (6186-13369)	14 400 (9160-19752)	47.5%	184 (117-252)	209 (133-287)	13-5
Alcohol use disorders	10 470 (7173-14 644)	13 826 (9248-19212)	32.1%	197 (135-276)	201 (134-279)	1.6
Alcohol dependence	10385 (7086-14556)	13735 (9164-19108)	32.3%	196 (134-275)	199 (133-277)	1.8
Fetal alcohol syndrome	85 (49-133)	91 (55-138)	6.9%	2 (1-3)	1 (1-2)	-17-7
Drug use disorders	11764 (8388-15468)	16 412 (11 836-21 583)	39.5%	222 (158-292)	238 (172-313)	7-3
Opioid use disorders	4812 (3350-6281)	7170 (5143-9257)	49.0%	91 (63-118)	104 (75-134)	14.6
Cocaine use disorders	800 (475-1214)	1085 (633-1639)	35.7%	15 (9-23)	16 (9-24)	4.4
Amphetamine use disorders	1894 (1067-2955)	2596 (1460-3957)	37-1%	36 (20-56)	38 (21-57)	5.5
Cannabis use disorders	1693 (1105-2418)	2057 (1348-2929)	21-5%	32 (21-46)	30 (20-43)	-6.5
Other drug use disorders	2565 (1583-3817)	3503 (2108-5170)	36.6%	48 (30-72)	51 (31-75)	5.1
Unipolar depressive disorders	54010 (40381-68450)	74264 (55 670-94240)	37-5%	1019 (762-1291)	1078 (808-1368)	5.8
Major depressive disorder	46 139 (34 517-58 427)	63 179 (47 779-80 891)	36-9%	870 (651-1102)	917 (693-1174)	5-4
Dysthymia	7871 (5266-10858)	11 084 (7297-15 447)	40-8%	148 (99-205)	161 (106-224)	8-4
Bipolar affective disorder	9129 (5757-13169)	12867 (8084-18654)	40.9%	172 (109-248)	187 (117-271)	8-5
Anxiety disorders	19 664 (13 868-26 820)	26 826 (18 779-36 795)	36-4%	371 (262-506)	389 (273-534)	5-0
Eating disorders	1120 (749–1554)	1956 (1316-2742)	74-6%	21 (14-29)	28 (19-40)	34-3
Anorexia nervosa	95 (65–136)	188 (125–265)	97-1%	2 (1-3)	3 (2-4)	51.7
Bulimia nervosa	1025 (687–1417)	1768 (1183–2480)	72.5%	19 (13–27)	26 (17–36)	32.7
Pervasive development disorders	5918 (4133-8130)	7666 (5355–10565)	29.5%	112 (78–153)	111 (78–153)	-0.3
Autism	3088 (2119-4260)	4007 (2752-5563)	29.8%	58 (40–80)	58 (40-81)	-0.2
rivelatii	3000 (222) 4200)	100, (=,)= 3303)			(Continues	

	All ages YLDs (thousands)		The state of	YLDs (per 100 000)		
	1990	2010	%∆	1990	2010	%∆
Continued from previous page)						777
Asperger's syndrome	2830 (1917-4016)	3659 (2463-5150)	29.3%	53 (36-76)	53 (36-75)	-0.5%
Childhood behavioural disorders	5472 (3277-8359)	6245 (3785-9347)	14.1%	103 (62-158)	91 (55-136)	-12-29
Attention-deficit hyperactivity disorder	424 (244-667)	491 (280-775)	15.8%	8 (5-13)	7 (4-11)	-10-9
Conduct disorder	5047 (2960-7840)	5753 (3428-8748)	14.0%	95 (56-148)	84 (50-127)	-12-3
Idiopathic intellectual disability	1247 (746-1924)	1043 (572-1687)	-16-4%	24 (14-36)	15 (8-24)	-35.79
Other mental and behavioural disorders	822 (485-1307)	1121 (661-1774)	36-4%	16 (9-25)	16 (10-26)	5.0
Diabetes, urogenital, blood, and endocrine diseases	38 626 (28 236-51 159)	56 924 (42 172-75 399)	47-4%	729 (533-965)	826 (612-1094)	13.4
Diabetes mellitus	12 412 (8403-17 524)	20758 (14415-28762)	67-2%	234 (158-331)	301 (209-417)	28-7
Uncomplicated diabetes mellitus	4260 (2420-6828)	6569 (3684-10380)	54-2%	80 (46-129)	95 (53-151)	18-7
Diabetic foot	209 (108-356)	308 (160-518)	47.1%	4 (2-7)	4 (2-8)	13-2
Diabetic neuropathy	7325 (4967-10520)	11914 (7977-17035)	62.6%	138 (94-198)	173 (116-247)	25-2
Amputation due to diabetes mellitus	392 (192-669)	905 (481-1427)	130-9%	7 (4-13)	13 (7-21)	77-6
Vision loss due to diabetes mellitus	227 (166-307)	1062 (795-1395)	368-6%	4 (3-6)	15 (12-20)	260-6
Acute glomerulonephritis	1 (0-2)	1 (0-2)	1.6%	<0.5 (0-0.5)	<0.5 (0-0.5)	-21-8
Chronic kidney diseases	2558 (1900-3288)	4018 (2972-5204)	57-1%	48 (36-62)	58 (43-76)	20-9
Chronic kidney disease due to diabetes mellitus	621 (453-796)	1003 (740-1317)	61.5%	12 (9-15)	15 (11–19)	24-2
Stage IV chronic kidney disease due to diabetes mellitus	88 (58-126)	141 (94-205)	60-5%	2 (1–2)	2 (1–3)	23.5
End-stage renal disease due to diabetes mellitus	388 (270-506)	626 (436-817)	61.5%	7 (5-10)	9 (6-12)	24-2
Anaemia due to chronic kidney disease stage III from diabetes mellitus	145 (79-237)	235 (126–378)	62-0%	3 (1-4)	3 (2-5)	24.7
Chronic kidney disease due to hypertension	550 (411-711)	872 (645-1123)	58.4%	10 (8-13)	13 (9-16)	21.9
Stage IV chronic kidney disease due to hypertension	88 (59-128)	138 (93-198)	56.7%	2 (1–2)	2 (1-3)	20.6
End-stage renal disease due to hypertension	326 (225-422)	515 (359-670)	58-0%	6 (4-8)	7 (5-10)	21-6
Anaemia due to chronic kidney disease stage III from hypertension	136 (77–222)	219 (124–354)	60-6%	3 (1-4)	3 (2-5)	23.6
Chronic kidney disease unspecified	1386 (1032-1800)	2143 (1585-2779)	54.6%	26 (19-34)	31 (23-40)	19.0
Stage IV unspecified or other chronic kidney disease	229 (154-335)	352 (233-506)	53.9%	4 (3-6)	5 (3-7)	18-4
End-stage renal disease from unspecified or other chronic kidney disease	799 (555–1042)	1242 (872–1607)	55.5%	15 (10–20)	18 (13-23)	19-6
Anaemia due to unspecified or other chronic kidney disease stage III	359 (208–579)	549 (314-889)	53.1%	7 (4–11)	8 (5-13)	17-8
Urinary diseases and male infertility	4651 (3057-7025)	8188 (5398-11978)	76.0%	88 (58-133)	119 (78-174)	35.59
Tubulointerstitial nephritis, pyelonephritis, and urinary tract infections	156 (84-269)	207 (109–360)	33-2%	3 (2-5)	3 (2-5)	2.59
Urolithiasis	480 (306-842)	716 (447-1425)	49.1%	9 (6-16)	10 (6-21)	14.79
Urolithiasis episodes	204 (107-526)	225 (104-918)	10.5%	4 (2-10)	3 (2-13)	-15.09
Chronic urolithiasis	277 (156-443)	491 (276-785)	77-5%	5 (3-8)	7 (4-11)	36.69
Benign prostatic hyperplasia	3726 (2392-5645)	6834 (4377-10179)	83.4%	70 (45-106)	99 (64-148)	41.19
Male infertility	126 (50-270)	173 (70-365)	36.9%	2 (1-5)	3 (1-5)	5.39
Other urinary diseases	162 (103-267)	258 (167-415)	58-8%	3 (2-5)	4 (2-6)	22-29
Gynaecological diseases	7671 (4880-11715)	10 042 (6226-15 619)	30-9%	145 (92-221)	146 (90-227)	0.79
Uterine fibroids	2341 (1568-3340)	3037 (1967-4551)	29.7%	44 (30-63)	44 (29-66)	-0-29
Uterine fibroids	934 (401-1852)	1527 (664-3059)	63-5%	18 (8-35)	22 (10-44)	25-89
Anaemia due to uterine fibroids	1407 (943-2023)	1509 (1000-2199)	7-3%	27 (18-38)	22 (15-32)	-17-49
Polycystic ovarian syndrome	2027 (971-3786)	2756 (1312-5212)	35.9%	38 (18-71)	40 (19-76)	4-69
Polycystic ovarian syndrome	1982 (931-3747)	2694 (1245-5171)	35-9%	37 (18-71)	39 (18-75)	4.69
Infertility due to polycystic ovarian syndrome	45 (18-95)	62 (25–128)	37-5%	1 (0-2)	1 (0-2)	5.89
Female infertility	91 (36–189)	125 (50-259)	37-6%	2 (1-4)	2 (1-4)	5.99
Endometriosis	404 (142-738)	544 (188–1007)	34-6%	8 (3-14)	8 (3–15)	3.59
Endometriosis	388 (129-715)	522 (166–974)	34.4%	7 (2-13)	8 (2-14)	3.49
		1	-11"	. (/		on next pa

	All ages YLDs (thousands)			YLDs (per 100 000)		
	1990	2010	%∆	1990	2010	%∆
Continued from previous page)						
Infertility due to endometriosis	16 (6-35)	22 (9-46)	37-8%	<0.5 (0-1)	<0.5 (0-1)	6.09
Genital prolapse	1339 (544-2686)	1811 (741-3649)	35-2%	25 (10-51)	26 (11-53)	4.19
Premenstrual syndrome	983 (49-2592)	1249 (63-3337)	27.0%	19 (1-49)	18 (1-48)	-2.39
Other gynaecological diseases	485 (330-703)	520 (345-759)	7.3%	9 (6-13)	8 (5-11)	-17-4
Haemoglobinopathies and haemolytic anaemias	8271 (5746-11276)	10 197 (7166-13 843)	23.3%	156 (108-213)	148 (104-201)	-5.1
Thalassaemias	3725 (2499-5279)	4636 (3098-6621)	24.4%	70 (47-100)	67 (45-96)	-4.2
β-thalassaemia major	31 (17-56)	33 (19-59)	7.9%	1 (0-1)	<0.5 (0-1)	-16-9
Haemoglobin E/β-thalassaemia	22 (14-34)	24 (15-37)	8.8%	<0.5 (0-1)	<0.5 (0-1)	-16-3
Haemoglobin H/β-thalassaemia	10 (6-16)	10 (6-16)	3.7%	<0.5 (0-0.5)	<0.5 (0-0.5)	-20-2
Anaemia due to thalassaemias	3653 (2427-5219)	4557 (3024-6530)	24.7%	69 (46-98)	66 (44-95)	-4-0
Heart failure due to thalassaemias	10 (6–14)	13 (8-19)	34.1%	<0.5 (0-0.5)	<0.5 (0-0.5)	3.2
Sickle cell disorders	2647 (1829-3615)	3665 (2612-4949)	38.5%	50 (34-68)	53 (38-72)	6.5
Homozygous sickle cell and severe sickle cell/β-thalassaemia	334 (238-441)	546 (389–736)	63.8%	6 (4-8)	8 (6–11)	26-1
Haemoglobin sickle cell disorders	78 (54-107)	130 (88-182)	65.5%	1 (1-2)	2 (1-3)	27-3
Mild sickle cell/β-thalassaemia	26 (18-37)	38 (27-53)	43.8%	<0.5 (0-1)	1 (0-1)	10-6
Anaemia due to sickle cell disorders	2211 (1439-3181)	2954 (1957-4240)	33.6%	42 (27-60)	43 (28-62)	2.8
G6PD deficiency	120 (81-174)	146 (97-210)	22.1%	2 (2-3)	2 (1-3)	-6-1
Anaemia due to G6PD deficiency	116 (77-171)	141 (93-205)	21.5%	2 (1-3)	2 (1-3)	-6-5
Heart failure due to G6PD deficiency	4 (2-6)	5 (3-8)	40-2%	<0.5 (0-0.5)	<0.5 (0-0.5)	7.8
Other haemoglobinopathies and haemolytic anaemias	1779 (1193-2565)	1750 (1171-2503)	-1.6%	34 (23-48)	25 (17-36)	-24-3
Anaemia due to other haemoglobinopathies and haemolytic anaemias	1757 (1173-2545)	1720 (1138-2483)	-2-1%	33 (22-48)	25 (17–36)	-24-7
Heart failure due to other haemoglobinopathies and haemolytic anaemias	22 (14-32)	31 (20-45)	39.5%	<0.5 (0-1)	<0.5 (0-1)	7-4
Other endocrine, nutritional, blood, and immune disorders	3063 (2256-4177)	3721 (2713–5114)	21-5%	58 (43-79)	54 (39-74)	-6.5
Other endocrine, nutritional, blood, and immune disorders	1254 (739–1952)	1919 (1133–2991)	53-0%	24 (14-37)	28 (16-43)	17-7
Anaemia due to other endocrine, nutritional, blood, and immune disorders	1777 (1187-2562)	1756 (1166-2542)	-1.2%	34 (22-48)	25 (17–37)	-23.9
Heart failure due to other endocrine, nutritional, blood, and immune disorders	33 (22-47)	48 (33-69)	46.1%	1 (0-1)	1 (0-1)	12-4
Musculoskeletal disorders	114719 (87 053-145 247)	165 955 (126 364 - 208 779)	44.7%	2164 (1642–2740)	2409 (1834-3030)	11-3
Rheumatoid arthritis	2566 (1831–3381)	3776 (2672-4954)	47.1%	48 (35-64)	55 (39-72)	13.2
Osteoarthritis	10 449 (7100-14788)	17135 (11884-24256)	64.0%	197 (134–279)	249 (172-352)	26-2
Osteoarthritis of the hip	1821 (1200–2616)	2917 (1945-4389)	60.2%	34 (23-49)	42 (28-64)	23-2
Osteoarthritis of the knee	8627 (5929–12276)	14218 (9809-19968)	64.8%	163 (112–232)	206 (142-290)	26-8
Low back and neck pain	82 111 (56 962-110 433)	116704 (80 615-156 527)	42.1%	1549 (1074–2083)	1694 (1170–2272)	9-2
Low back pain	58 245 (39 934-78 139)	83 063 (56 632-111 880)	42.6%	1099 (753-1474)	1206 (822–1624)	9.7
Neck pain	23 866 (16 535-33 105)	33 640 (23 469-46 476)	41.0%	450 (312-624)	488 (341-675)	8.5
Gout	76 (48–112)	114 (72–167)	49.3%	1 (1-2)	2 (1–2)	14.9
Other musculoskeletal disorders	19517 (16148-22127)	28 226 (23 201-31 884)	44.6%	368 (305-417)	410 (337-463)	11.3
Other non-communicable diseases	66 478 (45 586-97 937)	86771 (59561–128605)	30.5%	1254 (860–1847)	1259 (864–1867)	0-4
Congenital anomalies	2620 (2088-3333)	3279 (2594-4167)	25.2%	49 (39-63)	48 (38-60)	-3.7
Neural tube defects	569 (330-901)	754 (439-1142)	32.6%	11 (6–17)	11 (6–17)	2.0
Congenital heart anomalies	498 (350-711)	563 (388-804)	13.0%	9 (7-13)	8 (6–12)	-13-0
Congenital heart anomalies	189 (86-354)	226 (103-425)	19.1%	4 (2-7)	3 (1-6)	-8.3
Heart failure due to congenital heart anomalies	308 (203-442)	337 (221-486)	9.3%	6 (4-8)	5 (3-7)	-15.9
Cleft lip and cleft palate	259 (180-362)	254 (181-346)	-1.7%	5 (3-7)	4 (3-5)	-24-4
Down's syndrome	462 (306-664)	627 (425-888)	35.7%	9 (6-13)	9 (6-13)	4.4
Other chromosomal abnormalities	191 (127-274)	276 (182-392)	44.1%	4 (2-5)	4 (3-6)	10.8

	All ages YLDs (thousands)		THE YOU	YLDs (per 100 000)		
	1990	2010	%∆	1990	2010	%∆
Continued from previous page)						
Turner syndrome	3 (1-6)	4 (2-8)	35.6%	<0.5 (0-0.5)	<0.5 (0-0.5)	4.39
Klinefelter syndrome	5 (2-10)	6 (3–14)	38.7%	<0.5 (0-0.5)	<0.5 (0-0.5)	6.89
Chromosomal unbalanced rearrangements	184 (123-261)	265 (176-377)	44.3%	3 (2-5)	4 (3-5)	11.19
Other congenital anomalies	642 (464-868)	806 (596-1053)	25.6%	12 (9-16)	12 (9-15)	-3.39
Other congenital anomalies	437 (325-580)	595 (446-775)	36.4%	8 (6-11)	9 (6-11)	4.9
Hearing loss due to other congenital anomalies	225 (142-336)	240 (152-363)	6.6%	4 (3-6)	3 (2-5)	-17-9
Skin and subcutaneous diseases	26 273 (16 798-40 932)	33744 (21503-52280)	28-4%	496 (317-772)	490 (312-759)	-1.2
Eczema	6890 (3508-10872)	8897 (4518-14049)	29.1%	130 (66-205)	129 (66-204)	-0.6
Psoriasis	742 (371-1179)	1059 (528-1690)	42-8%	14 (7-22)	15 (8-25)	9.8
Cellulitis	302 (126-648)	376 (163-831)	24.5%	6 (2-12)	5 (2-12)	-4.29
Abscess, impetigo, and other bacterial skin diseases	1038 (473-2016)	1322 (599-2511)	27-4%	20 (9-38)	19 (9-36)	-1.9
Impetigo	871 (417-1624)	1088 (514-2048)	24.9%	16 (8-31)	16 (7-30)	-3.9
Abscess and other bacterial skin diseases cases	167 (54-386)	235 (78-539)	40.8%	3 (1-7)	3 (1-8)	8-39
Scabies	1881 (956-3384)	1580 (807-2792)	-16.0%	35 (18-64)	23 (12-41)	-35-4
Fungal skin diseases	1618 (532-3754)	2303 (740-5435)	42.3%	31 (10-71)	33 (11-79)	9.5
Viral skin diseases	2354 (1058-4369)	2731 (1203-4941)	16.0%	44 (20-82)	40 (17-72)	-10.79
Molluscum contagiosum	289 (88-702)	270 (85-645)	-6-6%	5 (2-13)	4 (1-9)	-28-19
Viral warts	2065 (816-3960)	2461 (984-4720)	19.2%	39 (15-75)	36 (14-69)	-8.3
Acne vulgaris	3281 (1545-6205)	4002 (1869-7575)	22-0%	62 (29-117)	58 (27-110)	-6-2
Alopecia areata	1002 (313-1906)	1352 (424-2567)	35-0%	19 (6-36)	20 (6-37)	3-9
Pruritus	1433 (682-2676)	2086 (1004-3951)	45-6%	27 (13-50)	30 (15-57)	12.19
Urticaria	1968 (757-3431)	2600 (980-4441)	32.1%	37 (14-65)	38 (14-64)	1.6
Decubitus ulcer	320 (165-524)	476 (237-779)	48.8%	6 (3-10)	7 (3-11)	14-5
Other skin and subcutaneous diseases	3445 (1638-6437)	4961 (2324-9239)	44.0%	65 (31-121)	72 (34-134)	10-8
Sense organ diseases	25169 (18140-35220)	34733 (25167-47663)	38.0%	475 (342-664)	504 (365-692)	6-29
Glaucoma	443 (338-561)	943 (725-1178)	112.7%	8 (6-11)	14 (11–17)	63.79
Cataracts	4225 (3283-5364)	4732 (3647-6010)	12.0%	80 (62–101)	69 (53-87)	-13.8
Macular degeneration	513 (388-647)	1329 (1026-1668)	158-9%	10 (7-12)	19 (15-24)	99-29
Refraction and accommodation disorders	3608 (2688-4762)	5593 (4117-7468)	55-0%	68 (51-90)	81 (60–108)	19-39
Other hearing loss	12 211 (7258-19 495)	15761 (9455-25210)	29.1%	230 (137–368)	229 (137–366)	-0.79
Other vision loss	4069 (2171-7180)	6240 (3260-11208)	53.4%	77 (41–135)	91 (47–163)	18-0
Other sense organ diseases	100 (34-231)	136 (46-309)	35.4%	2 (1-4)	2 (1-4)	4.29
Oral disorders	12 417 (6824-20 984)	15 015 (7795-26 482)	20.9%	234 (129-396)	218 (113-384)	-7.09
Dental caries	3704 (1523-7150)	4984 (2086-9356)	34.5%	70 (29–135)	72 (30–136)	3.59
Dental caries of baby teeth	403 (164-774)	425 (172-818)	5.7%	8 (3-15)	6 (3-12)	-18.79
Dental caries of permanent teeth	3302 (1347-6455)	4559 (1907-8554)	38.1%	62 (25–122)	66 (28–124)	6.29
Periodontal disease	3440 (1310-7305)	5410 (2051-11286)	57-3%	65 (25–138)	79 (30–164)	21.09
Edentulism	5273 (3100-8127)	4621 (2678-7296)	-12-4%	99 (58–153)	67 (39–106)	-32-69
Injuries	34 068 (24 209-47 034)	47162 (32958-66050)	38.4%	643 (457-887)	685 (478-959)	6.59
Transport injuries	12 062 (8524-16 826)	16 268 (11 304-22 717)	34.9%	228 (161-317)	236 (164-330)	3.89
Road injury	10 363 (7315-14 487)	13 485 (9362-18 950)	30.1%	195 (138-273)	196 (136–275)	0.19
Pedestrian injury by road vehicle	3106 (2183-4360)	4520 (3139–6367)	45.6%	59 (41–82)	66 (46-92)	12.09
Pedal cycle vehicle	755 (536–1056)	1025 (714–1436)	35.7%	14 (10-20)	15 (10-21)	4.49
Motorised vehicle with two wheels	1750 (1234–2435)	2224 (1529–3133)	27-1%	33 (23–46)	32 (22–45)	-2.29
Motorised vehicle with three or more wheels	4138 (2901–5793)	5792 (4041-8114)	40-0%	78 (55-109)	84 (59–118)	7.79
Road injury other	1440 (1 013–2 020)	1196 (824–1673)	-16-9%	27 (19-38)	17 (12-24)	-36.1%
Other transport injury	1699 (1184-2386)	2783 (1902–3872)	63.8%	32 (22–45)	40 (28–56)	26.09
Unintentional injuries other than transport injuries	19 036 (13 233-26 794)	26 620 (18 472-37 641)	39.8%	359 (250–505)	386 (268-546)	7.69
Falls	13324 (9110-18725)	19 459 (13 559-27 481)	46.0%	251 (172–353)	282 (197–399)	12.49
Drowning	233 (161–326)	281 (191–391)	20-9%	4 (3-6)	4 (3-6)	-7.09
	-55 (201-520)	TOT (T2T-22T)	20.970	+ (3-0)	4 (3-0)	-/-05

	All ages YLDs (thousands)			YLDs (per 100 000)		
	1990	2010	%Δ	1990	2010	%Δ
(Continued from previous page)	THE PROPERTY OF THE PARTY	A Property of	danistics.	METON PSO INVESTOR	no varied that a Same	Ac III
Fire, heat, and hot substances	1010 (637-1575)	1398 (857-2232)	38-4%	19 (12-30)	20 (12-32)	6.59
Poisonings	323 (210-470)	417 (276-621)	29-3%	6 (4-9)	6 (4-9)	-0.59
Exposure to mechanical forces	922 (599-1387)	1021 (662-1490)	10-8%	17 (11-26)	15 (10-22)	-14.7
Mechanical forces (firearm)	526 (346-784)	467 (305-676)	-11-2%	10 (7-15)	7 (4-10)	-31.7
Mechanical forces (other)	710 (460-1074)	910 (588-1336)	28.2%	13 (9-20)	13 (9-19)	-1.3
Adverse effects of medical treatment	585 (401-824)	1088 (727-1537)	85-9%	11 (8-16)	16 (11-22)	43.1
Animal contact	437 (293-634)	234 (154-329)	-46-4%	8 (6-12)	3 (2-5)	-58.7
Animal contact (venomous)	355 (233-526)	168 (110-242)	-52-5%	7 (4-10)	2 (2-4)	-63-4
Animal contact (non-venomous)	82 (55-119)	66 (44-93)	-20-0%	2 (1-2)	1 (1-1)	-38-4
Unintentional injuries not classified elsewhere	2202 (1484-3108)	2720 (1866-3827)	23-5%	42 (28-59)	39 (27-56)	-4-9
Self-harm and interpersonal violence	1571 (1066-2188)	1985 (1366-2726)	26-4%	30 (20-41)	29 (20-40)	-2.8
Self-harm	308 (209-428)	407 (278-577)	32-3%	6 (4-8)	6 (4-8)	1.8
Interpersonal violence	1263 (840-1775)	1578 (1085-2180)	24-9%	24 (16-33)	23 (16-32)	-3-9
Assault by firearm	504 (336-714)	587 (404-808)	16.5%	10 (6-13)	9 (6-12)	-10-4
Assault by sharp object	368 (245-516)	540 (369-743)	46.8%	7 (5-10)	8 (5-11)	12-9
Assault by other means	543 (362-758)	678 (464-940)	25.0%	10 (7-14)	10 (7-14)	-3-9
Forces of nature, war, and legal intervention	1399 (903-2080)	2289 (1550-3341)	63.6%	26 (17-39)	33 (22-48)	25.9
Exposure to forces of nature	173 (110-269)	2187 (1480-3210)	1164-7%	3 (2-5)	32 (21-47)	873-1
Collective violence and legal intervention	1226 (779-1854)	102 (66-153)	-91.7%	23 (15-35)	1 (1-2)	-93-6

Data are YLDs (95% uncertainty interval) or percentage change (%Δ). G6PD=glucose-6-phosphate dehydrogenase deficiency. E coli=Escherichia coli. H influenzae=Haemophilus influenzae. S oneumoniae=Streetococcus oneumoniae.

Table 2: Global years lived with disability (YLDs) for a comprehensive set of 289 causes and select sequelae in 1990 and 2010, for all ages, both sexes combined, and per 100 000

and ageing scenario is the difference in YLDs due to epidemiological change in age-specific and sex-specific YLDs per person. Each of these three differences is also presented as a percentage change with reference to the 1990 YLD estimate. Further details about the data and methods used for specific causes of YLDs are available on request from the corresponding author.

Role of the funding source

The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all of the data in the study and the final responsibility to submit for publication.

Results

Global prevalence for all ages combined in 2010 across the 1160 sequelae varied from fewer than one case per 1 million people to 350 000 cases per 1 million people. 58 sequelae each affected more than 1% of the global population. Table 1 shows the global prevalence of the 50 most common sequelae in 2010. Of these sequelae, four were oral health disorders (dental caries of permanent teeth, chronic periodontitis, dental caries of baby teeth, and edentulism). Four skin diseases were also very common: fungal skin disease, acne vulgaris, pruritus, and eczema; collectively these disorders affected 2·1 billion individuals (table 1). The number of individuals affected

by tension-type headaches or migraine was also very large—these neurological causes respectively ranked as the second and third most common. Low back pain, neck pain, other musculoskeletal, and osteoarthritis of the knee were also very common (table 1). Hearing loss affected 1.3 billion people and vision loss affected 661 million people. Two mental and behavioural disorders, anxiety and major depressive disorder, were in the top 30 most common causes. Two respiratory disorders, COPD and asthma, were also highly prevalent. Although prevalences varied substantially across communities, iron-deficiency anaemia affected 14.9% and infection with schistosomiasis affected 3.5% of the world's population. Five of the top 50 most common sequelae affected only one sex: genital prolapse, uterine fibroids, benign prostatic hyperplasia, premenstrual syndrome, and polycystic ovarian disease. Table 1, however, shows prevalences at the level of only sequelae and not at the level of disease or injuries. Disorders such as chronic kidney diseases (CKD) does not appear in the top 30 causes because, at the sequelae level, we have separate estimates for CKD from hypertension, CKD from diabetes, and CKD from other causes.

We detected a huge range of severity across sequelae with similar prevalence when comparing prevalence rate per 100 000 individuals on a log scale for each sequela compared with the average disability weight (appendix p 36). In general, more severe disorders were less common than less severe disorders, but there were notable

Sri Lanka (Prof S D Dharmaratne): The University of Liverpool. Liverpool, UK (M Dherani PhD): Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (C Diaz-Torne MD): University of Ulster, Ulster, UK (Prof H Dolk DrPH. M Loane MSc): Federal Ministry of Health, Khartoum, Sudan (S Eltahir Ali Mcs): Hospital Maciel Montevideo Uruguay (P Espindola MD): Emerald Public Health Consulting Services Ltd, Abuja, Nigeria (S E Ewoigbokhan MPH): Digestive Disease Research Center (Prof R Malekzadeh MD). Tehran University of Medical Sciences, Tehran, Iran (F Farzadfar MD. M Moradi-Lakeh MD): National Institute for Stroke and Applied Neurosciences (Prof V Feigin MD), Auckland Technical University, Auckland, New Zealand (R Krishnamurthi PhD. E Witt MSc): Medical School (GV Polanczyk MD), Federal University of São Paulo, São Paulo, Brazil (C P Ferri PhD): Carnegie Mellon University. Pittsburgh, PA, USA (S Flaxman BA); Royal Life